{"cells":[{"cell_type":"code","source":["dbutils.fs.ls('/FileStore/tables')"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"911882d4-3a93-4420-8281-9040832a9bf0"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[1]: [FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019/', name='clinicaltrial_2019/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019.csv', name='clinicaltrial_2019.csv', size=42400056, modificationTime=1650102313000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019_csv.gz', name='clinicaltrial_2019_csv.gz', size=10060669, modificationTime=1649091155000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020/', name='clinicaltrial_2020/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020_csv.gz', name='clinicaltrial_2020_csv.gz', size=10981608, modificationTime=1649091285000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021/', name='clinicaltrial_2021/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.csv', name='clinicaltrial_2021.csv', size=50359696, modificationTime=1652353022000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021_csv.gz', name='clinicaltrial_2021_csv.gz', size=11921810, modificationTime=1649091475000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023/', name='clinicaltrial_2023/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/mesh/', name='mesh/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/mesh.csv', name='mesh.csv', size=5295548, modificationTime=1649693608000),\n FileInfo(path='dbfs:/FileStore/tables/pharma/', name='pharma/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/pharma-1.csv', name='pharma-1.csv', size=678999, modificationTime=1651312714000),\n FileInfo(path='dbfs:/FileStore/tables/pharma-2.csv', name='pharma-2.csv', size=678999, modificationTime=1651674902000),\n FileInfo(path='dbfs:/FileStore/tables/pharma.csv', name='pharma.csv', size=678999, modificationTime=1651730899000),\n FileInfo(path='dbfs:/FileStore/tables/pharma2/', name='pharma2/', size=0, modificationTime=0)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[1]: [FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019/', name='clinicaltrial_2019/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019.csv', name='clinicaltrial_2019.csv', size=42400056, modificationTime=1650102313000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019_csv.gz', name='clinicaltrial_2019_csv.gz', size=10060669, modificationTime=1649091155000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020/', name='clinicaltrial_2020/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020_csv.gz', name='clinicaltrial_2020_csv.gz', size=10981608, modificationTime=1649091285000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021/', name='clinicaltrial_2021/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.csv', name='clinicaltrial_2021.csv', size=50359696, modificationTime=1652353022000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021_csv.gz', name='clinicaltrial_2021_csv.gz', size=11921810, modificationTime=1649091475000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2023/', name='clinicaltrial_2023/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/mesh/', name='mesh/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/mesh.csv', name='mesh.csv', size=5295548, modificationTime=1649693608000),\n FileInfo(path='dbfs:/FileStore/tables/pharma/', name='pharma/', size=0, modificationTime=0),\n FileInfo(path='dbfs:/FileStore/tables/pharma-1.csv', name='pharma-1.csv', size=678999, modificationTime=1651312714000),\n FileInfo(path='dbfs:/FileStore/tables/pharma-2.csv', name='pharma-2.csv', size=678999, modificationTime=1651674902000),\n FileInfo(path='dbfs:/FileStore/tables/pharma.csv', name='pharma.csv', size=678999, modificationTime=1651730899000),\n FileInfo(path='dbfs:/FileStore/tables/pharma2/', name='pharma2/', size=0, modificationTime=0)]"]}}],"execution_count":0},{"cell_type":"code","source":["fileroot= \"clinicaltrial_2021_csv\"\nfileroot2=\"clinicaltrial_2021.csv\"\ndbutils.fs.cp(\"/FileStore/tables/\" + fileroot + \".gz\",\"file:/tmp/\")\nimport os\nos.environ[\"fileroot\"] = fileroot\nos.environ[\"fileroot2\"] = fileroot2"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"833175f5-d17d-4906-84ac-869629c064f6"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["%sh\ngzip  -d /tmp/$fileroot.gz\nmv /tmp/$fileroot /tmp/$fileroot2\nls /tmp"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"00a7abdb-cbf4-4c96-a93f-3708266032b5"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Rserv\nRtmp8asMoZ\nchauffeur-daemon-params\nchauffeur-daemon.pid\nchauffeur-env.sh\nclinicaltrial_2021.csv\ncustom-spark.conf\ndriver-daemon-params\ndriver-daemon.pid\ndriver-env.sh\nhsperfdata_root\nipykernel-connection-ReplId-13c06-3eacb-53df4-4.json\nipykernel-connection-ReplId-3073c-3bf8b-1bfcd-0.json\nipykernel-connection-ReplId-5296f-a2fa3-3357e-b.json\nsystemd-private-652a58decda84c93b7891feb4f7fd15f-apache2.service-KpcqYg\nsystemd-private-652a58decda84c93b7891feb4f7fd15f-ntp.service-NU8hKf\nsystemd-private-652a58decda84c93b7891feb4f7fd15f-systemd-logind.service-llRiyg\nsystemd-private-652a58decda84c93b7891feb4f7fd15f-systemd-resolved.service-HXe2Mh\ntmp.jZmaWbUmeu\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Rserv\nRtmp8asMoZ\nchauffeur-daemon-params\nchauffeur-daemon.pid\nchauffeur-env.sh\nclinicaltrial_2021.csv\ncustom-spark.conf\ndriver-daemon-params\ndriver-daemon.pid\ndriver-env.sh\nhsperfdata_root\nipykernel-connection-ReplId-13c06-3eacb-53df4-4.json\nipykernel-connection-ReplId-3073c-3bf8b-1bfcd-0.json\nipykernel-connection-ReplId-5296f-a2fa3-3357e-b.json\nsystemd-private-652a58decda84c93b7891feb4f7fd15f-apache2.service-KpcqYg\nsystemd-private-652a58decda84c93b7891feb4f7fd15f-ntp.service-NU8hKf\nsystemd-private-652a58decda84c93b7891feb4f7fd15f-systemd-logind.service-llRiyg\nsystemd-private-652a58decda84c93b7891feb4f7fd15f-systemd-resolved.service-HXe2Mh\ntmp.jZmaWbUmeu\n"]}}],"execution_count":0},{"cell_type":"code","source":["dbutils.fs.cp('file:/tmp/'+fileroot2, '/FileStore/tables/'+ fileroot2)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"511edc38-ecea-4c4e-be75-90cf371bf3ed"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[4]: True","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[4]: True"]}}],"execution_count":0},{"cell_type":"code","source":["dbutils.fs.head('/FileStore/tables/'+ fileroot2)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"d3b513c7-1a7c-4ae7-8a2d-e98dd8f508f7"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"[Truncated to first 65536 bytes]\nOut[5]: \"Id|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions\\r\\nNCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||\\r\\nNCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|\\r\\nNCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|\\r\\nNCT02758860|University of Roma La Sapienza|Active, not recruiting|Jun 2016|Sep 2020|Observational [Patient Registry]|Apr 2016|Diverticular Diseases,Diverticulum,Diverticulosis|\\r\\nNCT02757209|Consorzio Futuro in Ricerca|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate\\r\\nNCT02752438|Ankara University|Unknown status|May 2016|Jul 2017|Observational [Patient Registry]|Apr 2016|Hypoventilation|\\r\\nNCT02753543|Ruijin Hospital|Unknown status|Nov 2015|Nov 2019|Interventional|Apr 2016|Lymphoma|\\r\\nNCT02757508|Washington University School of Medicine|Completed|Mar 2016|Jul 2017|Interventional|Apr 2016||Vitamins\\r\\nNCT02753530|Orphazyme|Completed|Aug 2017|Jan 2021|Interventional|Apr 2016|Myositis|\\r\\nNCT02754817|Novo Nordisk A/S|Completed|Apr 2016|Oct 2016|Observational|Apr 2016|Diabetes Mellitus|Liraglutide,Xultophy\\r\\nNCT02759276|Daniel Alexandre Bottino|Completed|May 2015|Dec 2015|Observational|Apr 2016|Hypertension|\\r\\nNCT02750956|Bulent Ecevit University|Completed|Jun 2015|Mar 2016|Observational|Apr 2016|Periodontal Diseases|\\r\\nNCT02752113|Institut für Pharmakologie und Präventive Medizin|Completed|Apr 2016|May 2019|Interventional|Apr 2016|Diabetes Mellitus|Metformin,Empagliflozin,Linagliptin\\r\\nNCT02752698|The Third Xiangya Hospital of Central South University|Active, not recruiting|Jan 2015|Dec 2021|Interventional|Jun 2015|Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones|\\r\\nNCT02755779|Tel Aviv Medical Center|Unknown status|Jun 2016|Jun 2017|Observational|Apr 2016||\\r\\nNCT02750384|Medicines for Malaria Venture|Terminated|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02754609|James Cook University, Queensland, Australia|Completed|Sep 2016|Oct 2019|Interventional|Apr 2016|Hookworm Infections,Celiac Disease|\\r\\nNCT02755701|Soonchunhyang University Hospital|Unknown status|Jul 2016|Dec 2018|Interventional|Apr 2016|Ascites|\\r\\nNCT02751762|Member Companies of the Opioid PMR Consortium|Recruiting|Nov 2017|Oct 2022|Observational|Apr 2016|Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior|\\r\\nNCT02756299|Marmara University|Completed|Jun 2014|Apr 2015|Interventional|Apr 2016|Sleep Apnea Syndromes,Sleep Apnea|\\r\\nNCT02750709|Cycle Pharmaceuticals Ltd.|Completed|Oct 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02753907|Yonsei University|Completed|Jun 2015||Interventional|Apr 2016||\\r\\nNCT02755467|Cutera Inc.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Hemangioma|\\r\\nNCT02755298|University of Zurich|Completed|Oct 2016|Nov 2020|Interventional|Mar 2016|Hypertension|Acetazolamide\\r\\nNCT02759614|Guangdong Association of Clinical Trials|Unknown status|Apr 2016|Jun 2019|Interventional|Mar 2016|Carcinoma|Bevacizumab,Erlotinib Hydrochloride\\r\\nNCT02752815|Ruijin Hospital|Unknown status|Apr 2016|Jun 2020|Interventional|Apr 2016|Lymphoma|Prednisone,Cyclophosphamide,Rituximab,Vincristine,Epirubicin\\r\\nNCT02757131|The Cleveland Clinic|Completed|Jul 2016|Jul 2017|Interventional|Apr 2016|Iatrogenic Disease|\\r\\nNCT02758704|St. Justine's Hospital|Completed|Oct 2015|Jun 2021|Interventional|Apr 2016||\\r\\nNCT02750501|Alcresta Therapeutics, Inc.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02759913|Iron Horse Diagnostics, Inc.|Unknown status|Jan 2015|Dec 2016|Observational|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\\r\\nNCT02752724|VA Puget Sound Health Care System|Completed|Mar 2016|Apr 2018|Interventional|Mar 2016|Depressive Disorder,Depression|Ketamine,Methohexital\\r\\nNCT02758444|University of Colorado, Denver|Completed|Nov 2015|Feb 2019|Interventional|Apr 2016||Micronutrients,Trace Elements\\r\\nNCT02758067|H. Lundbeck A/S|Withdrawn|Jun 2016||Interventional|Apr 2016|Schizophrenia|Risperidone,Brexpiprazole\\r\\nNCT02759341|Ospedale San Giovanni Bellinzona|Completed|Feb 2016|Nov 2017|Interventional|Apr 2016|Myocardial Infarction,Cardiomyopathies,Microvascular Angina,Takotsubo Cardiomyopathy,Syndrome,Infarction|\\r\\nNCT02753803|Dong-A ST Co., Ltd.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016||Pioglitazone\\r\\nNCT02752490|The University of Texas Health Science Center, Houston|Completed|Apr 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02759562|Gilead Sciences|Terminated|Nov 2016|Jul 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02758262|Laval University|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016|Hyperphagia|\\r\\nNCT02754258|Children's Hospital of Eastern Ontario|Unknown status|Jan 2017|Dec 2018|Interventional|Apr 2016||Methylphenidate\\r\\nNCT02755207|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Apr 2016|Dec 2020|Observational|Mar 2016|Acute Coronary Syndrome,Syndrome|\\r\\nNCT02759900|The Skin Center Dermatology Group|Recruiting|Jan 2016|Jan 2023|Interventional|Apr 2016|Molluscum Contagiosum,Keratosis,Bowens Disease,Rosacea,Skin Diseases|\\r\\nNCT02752581|Mert Özcan|Completed|Jan 2009|Apr 2013|Interventional|Apr 2016|Hemarthrosis|\\r\\nNCT02759796|Instituto de Investigación Hospital Universitario La Paz|Completed|Nov 2015|Apr 2017|Interventional|Apr 2016|Necrosis,Neovascularization,Fat Necrosis|\\r\\nNCT02754063|University Hospital, Grenoble|Active, not recruiting|Jun 2016|Apr 2022|Interventional|Apr 2016|Brain Injuries,Wounds and Injuries|3\\r\\nNCT02750917|Foisor Orthopedics Clinical Hospital|Completed|Sep 2014|Mar 2015|Interventional|Feb 2016|Pain|Etoricoxib,Lornoxicam\\r\\nNCT02753569|Institute of Cancer Research, United Kingdom|Completed|May 2016|May 2020|Observational|Apr 2016||\\r\\nNCT02751255|VU University Medical Center|Active, not recruiting|Jul 2016|Mar 2022|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Tretinoin\\r\\nNCT02751528|NantBioScience, Inc.|Unknown status|Dec 2016|Dec 2020|Interventional|Apr 2016|Breast Neoplasms|Vaccines\\r\\nNCT02751619|University of Campania Luigi Vanvitelli|Completed|Jan 2013|Dec 2015|Interventional|Apr 2016|Pain|Lidocaine\\r\\nNCT02757833|Lawson Health Research Institute|Withdrawn|Feb 2019|Feb 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\\r\\nNCT02750761|Merck Sharp & Dohme Corp.|Completed|May 2016|Dec 2018|Interventional|Apr 2016|Infections,Bacterial Infections,Gram-Positive Bacterial Infections|Tedizolid phosphate,Tedizolid,Oxazolidinones\\r\\nNCT02752594|Sharda University|Completed|Apr 2015|Apr 2015|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02753452|Holland Bloorview Kids Rehabilitation Hospital|Unknown status|May 2015|Mar 2020|Interventional|Apr 2016||\\r\\nNCT02752763|Niğde State Hospital|Completed|Oct 2015|Mar 2016|Interventional|Mar 2016|Dry Eye Syndromes,Keratoconjunctivitis Sicca|Dextrans,Povidone,Ophthalmic Solutions,Lubricant Eye Drops\\r\\nNCT02753816|Spectrum Health Hospitals|Terminated|Apr 2016|Dec 2019|Interventional|Apr 2016|Burns|Tranexamic Acid\\r\\nNCT02751294|GlaxoSmithKline|Completed|May 2016|Aug 2016|Interventional|Apr 2016|Malaria|Tafenoquine\\r\\nNCT02756429|Hospices Civils de Lyon|Completed|Feb 2014|Jan 2018|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02750163|Università Politecnica delle Marche|Completed|Jul 2017|Jun 2019|Observational|Apr 2016|Shock|Acetaminophen\\r\\nNCT02751905|Biogen|Completed|Apr 2016|May 2016|Interventional|Apr 2016|Neuralgia|\\r\\nNCT02753153|University of Liege|Completed|May 2011|May 2015|Interventional|Apr 2016|Tooth Loss|\\r\\nNCT02750891|Sumitomo Dainippon Pharma Co., Ltd.|Completed|Apr 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Diffuse Intrinsic Pontine Glioma|\\r\\nNCT02751073|Mayo Clinic|Completed|Feb 2016|Jul 2018|Observational|Feb 2016|Infections,Communicable Diseases,Urinary Tract Infections,Prolapse,Pelvic Organ Prolapse|\\r\\nNCT02753114|University of British Columbia|Completed|Nov 2017|May 2018|Interventional|Apr 2016|Acute Pain|Ketamine\\r\\nNCT02752516|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016||\\r\\nNCT02752269|Medical University of Graz|Completed|Oct 2014|Jun 2019|Observational|Nov 2015|Sjogrens Syndrome,Hypertension,Vascular Diseases,Syndrome|\\r\\nNCT02754713|Hippocration General Hospital|Recruiting|Sep 2009|Dec 2025|Observational|Apr 2016|Pericarditis|\\r\\nNCT02759770|Beijing Anzhen Hospital|Completed|Jul 2017|Sep 2017|Observational|Apr 2016|Respiratory Distress Syndrome,Acute Lung Injury|\\r\\nNCT02755129|Medtronic BRC|Completed|Sep 2016|Jul 2017|Interventional|Mar 2016|Frailty|\\r\\nNCT02754674|Samsung Medical Center|Completed|May 2014|Dec 2017|Interventional|Feb 2015|Rupture|\\r\\nNCT02757521|Washington University School of Medicine|Terminated|Mar 2016|Dec 2016|Interventional|Apr 2016|Disease,Depression,Depressive Disorder,Bipolar Disorder|Nitrous Oxide\\r\\nNCT02750774|University of Modena and Reggio Emilia|Unknown status|Dec 2015|Dec 2016|Interventional|Apr 2016|Diabetes,Obesity,Pregnancy Complications,Fetal Macrosomia,Overweight,Birth Weight|\\r\\nNCT02754739|Samsung Medical Center|Completed|Apr 2014|Aug 2017|Interventional|Apr 2016|Diabetes Mellitus,Prediabetic State|Pravastatin\\r\\nNCT02758808|University of Michigan|Recruiting|Mar 2016|Oct 2023|Observational [Patient Registry]|Apr 2016|Lung Diseases,Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\\r\\nNCT02751840|Tel Hai College|Completed|Oct 2014|Apr 2016|Interventional|Apr 2016|Asymptomatic Diseases|Caffeine\\r\\nNCT02752451|University of Arizona|Completed|Mar 2015|Apr 2015|Interventional|Apr 2016||\\r\\nNCT02757599|Rigshospitalet, Denmark|Completed|Aug 2016|Jun 2017|Interventional|Apr 2016||\\r\\nNCT02753894|Astellas Pharma Inc|Completed|Jan 2008|Jun 2008|Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency,Hyperphosphatemia|\\r\\nNCT02757638|Texas A&M University|Active, not recruiting|Oct 2015|Oct 2021|Interventional|Feb 2016|Weight Loss|\\r\\nNCT02757378|Kevin Farrell|Completed|May 2015|Sep 2015|Interventional|Apr 2016|Back Pain,Low Back Pain|\\r\\nNCT02751489|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|\\r\\nNCT02759315|Merck Sharp & Dohme Corp.|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Uprifosbuvir,Ruzasvir\\r\\nNCT02754895|Massachusetts General Hospital|Completed|Oct 2014|May 2017|Interventional|Apr 2016|Acute Coronary Syndrome,Syndrome|\\r\\nNCT02750475|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\\r\\nNCT02755064|Adil Bharucha|Completed|Jun 2010|Nov 2013|Interventional|Apr 2016|Diabetes Mellitus|Erythromycin,Erythromycin Estolate,Erythromycin Ethylsuccinate,Erythromycin stearate,Erythromycin lactobionate\\r\\nNCT02758002|University of California, San Diego|Withdrawn|Jan 2016|Dec 2018|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02755142|medac GmbH|Completed|Feb 2000|Jun 2001|Interventional|Apr 2016|Glioma,Brain Neoplasms|Aminolevulinic Acid\\r\\nNCT02756364|Millennium Pharmaceuticals, Inc.|Completed|Jul 2016|Nov 2019|Interventional|Apr 2016|Breast Neoplasms|Fulvestrant\\r\\nNCT02759484|Rush University Medical Center|Unknown status|Mar 2015|Mar 2019|Interventional|Dec 2015|Hypertension,Diabetes Mellitus,Hyperglycemia|\\r\\nNCT02752061|Harvard School of Public Health (HSPH)|Completed|May 2016|Jul 2020|Interventional|Apr 2016||\\r\\nNCT02756598|Aarhus University Hospital|Completed|Jan 2015|Jun 2018|Interventional|Dec 2015||Sufentanil,Dsuvia,Propofol\\r\\nNCT02755727|Royal Devon and Exeter NHS Foundation Trust|Completed|Mar 2016|Sep 2017|Interventional|Apr 2016|Tennis Elbow|\\r\\nNCT02754882|Samsung Bioepis Co., Ltd.|Completed|Jul 2016|Oct 2018|Interventional|Mar 2016|Lung Neoplasms,Carcinoma|Paclitaxel,Bevacizumab,Carboplatin\\r\\nNCT02754778|Martin-Luther-Universität Halle-Wittenberg|Completed|Apr 2016|Mar 2021|Interventional|Apr 2016|Pre-Eclampsia,HELLP Syndrome,Syndrome|\\r\\nNCT02758171|Boehringer Ingelheim|Completed|May 2016|Aug 2016|Interventional|Apr 2016||Empagliflozin,Linagliptin\\r\\nNCT02755376|Samsung Medical Center|Completed|Jan 2014|Dec 2018|Interventional|Feb 2015||Hyaluronic Acid\\r\\nNCT02759016|Boehringer Ingelheim|Completed|Jun 2016|Jul 2019|Interventional|Apr 2016|Leukemia|BI 836826\\r\\nNCT02758457|University of Bologna|Completed|Jan 2008|Apr 2015|Interventional|Apr 2016||\\r\\nNCT02755519|Chongqing Medical University|Completed|May 2014|Oct 2016|Observational|Apr 2016|Hyperaldosteronism|\\r\\nNCT02758782|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2021|Interventional|Apr 2016|Spondylitis|Celecoxib,Golimumab\\r\\nNCT02756806|Cutera Inc.|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016||\\r\\nNCT02756156|Kahramanmaras Sutcu Imam University|Unknown status|Apr 2016|Aug 2016|Observational|Mar 2016|Humeral Fractures|\\r\\nNCT02759458|Rush University Medical Center|Completed|Nov 2013|Jan 2017|Interventional|Apr 2016|Rotator Cuff Injuries|\\r\\nNCT02750982|Brown, Theodore R., M.D., MPH|Completed|Jul 2016|Aug 2018|Interventional|Apr 2016|Parkinson Disease,Multiple Sclerosis,Alzheimer Disease,Brain Injuries,Spinal Cord Injuries,Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Huntington Disease,Sclerosis,Wounds and Injuries|\\r\\nNCT02751502|NYU Langone Health|Terminated|Jan 2017|Feb 2021|Interventional|Apr 2016|Hemiplegia|\\r\\nNCT02752087|Eli Lilly and Company|Completed|Apr 2016|May 2016|Interventional|Apr 2016||\\r\\nNCT02756858|Anavex Life Sciences Corp.|Completed|Mar 2016|Nov 2020|Interventional|Mar 2016|Alzheimer Disease|\\r\\nNCT02758249|Konkuk University Medical Center|Completed|Jan 2016|Jan 2016|Interventional|Feb 2016||Propofol,Sevoflurane\\r\\nNCT02754570|University of Colorado, Denver|Completed|Jul 2016|Feb 2018|Interventional|Apr 2016|Glaucoma,Ocular Hypertension,Hypertension|Pilocarpine\\r\\nNCT02754102|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\\r\\nNCT02751593|Peking University People's Hospital|Unknown status|Jan 2016|Dec 2017|Interventional|Apr 2016|Thrombocytopenia,Purpura|Dexamethasone\\r\\nNCT02757014|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\\r\\nNCT02753062|Asan Medical Center|Recruiting|Aug 2015|Aug 2023|Interventional|Apr 2016|Lymphoma|Rituximab,Bendamustine Hydrochloride\\r\\nNCT02752425|Hospices Civils de Lyon|Completed|May 2016|May 2018|Interventional|Apr 2016|Speech Disorders|\\r\\nNCT02757300|Marienhospital Osnabrück|Unknown status|May 2016|Jul 2017|Interventional|Apr 2016|Pharyngitis|\\r\\nNCT02754180|Peking Union Medical College Hospital|Unknown status|Mar 2016|Mar 2021|Interventional|Apr 2016|Adenocarcinoma,Pancreatic Neoplasms|Gemcitabine\\r\\nNCT02752321|Northwell Health|Terminated|Aug 2016|Dec 2017|Interventional|Apr 2016||\\r\\nNCT02753595|Eisai Inc.|Terminated|Jul 2016|Aug 2019|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02755246|Charite University, Berlin, Germany|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016|Cognitive Dysfunction|\\r\\nNCT02754115|Tata Memorial Centre|Recruiting|Apr 2016|Jan 2022|Observational|Mar 2016|Peritoneal Diseases|\\r\\nNCT02756897|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2024|Interventional|Apr 2016|Lymphoma,Leukemia|Venetoclax\\r\\nNCT02752334|Magrabi Eye & Ear Hospital|Completed|Sep 2015|Mar 2019|Interventional|Mar 2016||Magnesium Sulfate,Bupivacaine\\r\\nNCT02754791|Shaare Zedek Medical Center|Unknown status|May 2016|May 2017|Interventional|Apr 2016||\\r\\nNCT02754128|Holland Bloorview Kids Rehabilitation Hospital|Completed|Jun 2016|Oct 2017|Interventional|Apr 2016|Cerebral Palsy|\\r\\nNCT02751190|Umeå University|Completed|Sep 2013|Feb 2017|Observational [Patient Registry]|Apr 2016|Chronic Pain,Hernia|\\r\\nNCT02751645|Oregon Health and Science University|Unknown status|Jun 2016|May 2020|Interventional|Apr 2016||\\r\\nNCT02758184|Duke University|Terminated|Jun 2016|May 2018|Interventional|Apr 2016||\\r\\nNCT02751892|University of East Anglia|Completed|Oct 2013|Sep 2014|Interventional|Apr 2016|Colorectal Neoplasms|\\r\\nNCT02755324|Leiden University|Completed|Oct 2016|Jan 2019|Interventional|Apr 2016|Schistosomiasis|\\r\\nNCT02758886|Washington State University|Completed|Apr 2014||Interventional|Apr 2016|Stress|\\r\\nNCT02750072|Fraser Orthopaedic Research Society|Active, not recruiting|Sep 2016|Apr 2023|Interventional|Apr 2016|Patellofemoral Pain Syndrome,Fractures,Tibial Fractures|\\r\\nNCT02750332|Cycle Pharmaceuticals Ltd.|Completed|Nov 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02752529|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Mar 2016||Interventional|Mar 2016|Liver Cirrhosis|Tacrolimus\\r\\nNCT02759939|Dartmouth-Hitchcock Medical Center|Completed|Jul 2016|Jul 2017|Interventional|Feb 2016||\\r\\nNCT02757157|European Respiratory Society|Terminated|Oct 2016|Jan 2020|Interventional|Apr 2016|Lung Diseases,Pulmonary Disease|\\r\\nNCT02759627|Istanbul University|Completed|Nov 2014|Mar 2016|Interventional|Apr 2016|Stroke|\\r\\nNCT02752412|Sanofi|Completed|May 2016|Oct 2018|Interventional|Apr 2016|Diabetes Mellitus|Insulin,Metformin,Insulin Glargine,Lixisenatide\\r\\nNCT02756988|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\\r\\nNCT02751203|Lara McKenzie|Completed|Apr 2016|Dec 2017|Interventional|Mar 2016||\\r\\nNCT02753946|Nabriva Therapeutics AG|Completed|Apr 2016|May 2017|Interventional|Apr 2016|Infections,Communicable Diseases,Urinary Tract Infections,Pyelonephritis|Tazobactam,Piperacillin,Fosfomycin\\r\\nNCT02755480|University Health Network, Toronto|Terminated|Feb 2015|Feb 2017|Interventional|Mar 2015||\\r\\nNCT02753257|Valtari Bio|Unknown status|Sep 2016|Dec 2019|Observational|Apr 2016|Stroke|\\r\\nNCT02758691|Virginia Polytechnic Institute and State University|Completed|Dec 2015|May 2017|Interventional|Apr 2016||Insulin\\r\\nNCT02755623|Centre hospitalier de Ville-Evrard, France|Unknown status|May 2015|Dec 2018|Interventional|Apr 2016|Hallucinations,Schizophrenia|\\r\\nNCT02756234|Lancaster General Hospital|Completed|May 2016|Aug 2018|Observational|Apr 2016|Coronary Artery Disease|\\r\\nNCT02756091|University Hospital Inselspital, Berne|Recruiting|Aug 2016|May 2022|Observational [Patient Registry]|Apr 2016|Cerebrovascular Disorders|\\r\\nNCT02753491|Marmara University|Completed|Oct 2015|Mar 2016|Interventional|Apr 2016||\\r\\nNCT02752737|Medtronic Cardiac Rhythm and Heart Failure|Recruiting|May 2016|Dec 2024|Observational [Patient Registry]|Apr 2016|Atrial Fibrillation|\\r\\nNCT02758925|University Hospital, Caen|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Lymphoma|Cytarabine,Rituximab,Bendamustine Hydrochloride\\r\\nNCT02751723|Florian Lordick, MD|Unknown status|Sep 2014|Oct 2019|Observational|Apr 2016||\\r\\nNCT02751931|Astellas Pharma Europe B.V.|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Urinary Bladder|Mirabegron\\r\\nNCT02758847|Rabih A. Chaer|Recruiting|Sep 2016|Dec 2022|Interventional|Apr 2016|Ischemia|Paclitaxel,Albumin-Bound Paclitaxel\\r\\nNCT02757807|Eco Fusion|Unknown status|Jul 2016|Dec 2016|Interventional|Apr 2016|Erectile Dysfunction|\\r\\nNCT02755220|Shanghai Cingularbio Co. Ltd|Completed|Jan 2016|Apr 2019|Interventional|Apr 2016||\\r\\nNCT02758548|Novartis Pharmaceuticals|Completed|Mar 2016|May 2016|Interventional|Mar 2016||\\r\\nNCT02756845|Amgen|Recruiting|Aug 2017|Jun 2024|Interventional|Dec 2015|Neoplasms|Talimogene laherparepvec\\r\\nNCT02750605|Skane University Hospital|Active, not recruiting|Feb 2016|Dec 2021|Interventional|Jan 2016|Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Ischemia|\\r\\nNCT02756702|Aesculap AG|Active, not recruiting|Mar 2016|Dec 2022|Observational|Apr 2016|Osteoarthritis|\\r\\nNCT02752945|King's College London|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Depression,Depressive Disorder,Anxiety Disorders|\\r\\nNCT02759952|STZ eyetrial|Enrolling by invitation|Jan 2013|Dec 2025|Observational|Apr 2016|Retinitis,Retinitis Pigmentosa|\\r\\nNCT02754661|Medtronic - MITG|Completed|Sep 2016|Aug 2018|Interventional|Apr 2016|Colorectal Neoplasms|\\r\\nNCT02755441|Nils Hoyer|Recruiting|Apr 2016|Dec 2024|Observational|Apr 2016|Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\\r\\nNCT02750098|Sheba Medical Center|Unknown status|May 2016|Mar 2018|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02753179|Hospices Civils de Lyon|Completed|May 2016|Jan 2017|Interventional|Apr 2016|Vestibular Diseases|\\r\\nNCT02758509|Parc de Salut Mar|Completed|Jan 2010|Oct 2017|Observational|Apr 2016|Hepatitis C,Hepatitis|Interferons,Ritonavir,Ribavirin,Interferon-alpha,Interferon alpha-2,Sofosbuvir,Peginterferon alfa-2a,Ledipasvir,Simeprevir\\r\\nNCT02751970|Universidad de Valparaiso|Unknown status|Apr 2014|Apr 2018|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02753712|Mundipharma Research Limited|Completed|Jun 2016|Aug 2017|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Formoterol Fumarate\\r\\nNCT02751151|Inova Health Care Services|Completed|Feb 2016|May 2021|Interventional|Mar 2016|Skin Neoplasms|Aminolevulinic Acid\\r\\nNCT02757716|Sana Klinikum Offenbach|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Behavior|\\r\\nNCT02758652|Tampere University Hospital|Active, not recruiting|May 2016|May 2026|Observational|Apr 2016|Ovarian Neoplasms,Carcinoma|\\r\\nNCT02754206|Southern Methodist University|Terminated|Jan 2016|Sep 2021|Observational|Apr 2016|Post-Concussion Syndrome,Brain Concussion|\\r\\nNCT02752243|Peter Bader|Active, not recruiting|Mar 2016|Mar 2022|Interventional|Mar 2016|Leukemia,Preleukemia,Myelodysplastic Syndromes,Syndrome,Acute Disease|\\r\\nNCT02754856|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2021|Interventional|Apr 2016|Colorectal Neoplasms|Durvalumab,Ipilimumab,Tremelimumab,Immunoglobulins,Antibodies,Immunoglobulin G\\r\\nNCT02759861|University of Nebraska|Active, not recruiting|Aug 2016|Aug 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Sofosbuvir,Ledipasvir\\r\\nNCT02759679|Haukeland University Hospital|Unknown status|May 2016|Dec 2019|Interventional|Mar 2016|Lung Neoplasms|\\r\\nNCT02752932|Lawson Health Research Institute|Completed|Nov 2015|Oct 2017|Interventional|Feb 2016|Carcinoma,Squamous Cell Carcinoma of Head and Neck,Neoplasms|\\r\\nNCT02759445|RWTH Aachen University|Unknown status|Apr 2016|Oct 2016|Observational|Nov 2015||\\r\\nNCT02754622|Guy's and St Thomas' NHS Foundation Trust|Completed|Jul 2016|Dec 2016|Observational|Apr 2016|Critical Illness|\\r\\nNCT02756611|AbbVie|Active, not recruiting|Jun 2016|Sep 2022|Interventional|Apr 2016|Leukemia|Venetoclax\\r\\nNCT02758223|Wuerzburg University Hospital|Active, not recruiting|Apr 2016|Jun 2021|Interventional|Feb 2016|Leukemia,Myelodysplastic Syndromes|\\r\\nNCT02757079|Nobelpharma|Completed|Jun 2016|Jul 2018|Interventional|Apr 2016|Sleep Wake Disorders,Parasomnias,Disease,Neurodevelopmental Disorders|Melatonin\\r\\nNCT02754219|Dong-A ST Co., Ltd.|Completed|Sep 2016|Jan 2018|Interventional|Apr 2016|Liver Diseases|\\r\\nNCT02753101|Stanford University|Completed|Feb 2016|Feb 2017|Interventional|Apr 2016|Complex Regional Pain Syndromes,Reflex Sympathetic Dystrophy,Sciatica|\\r\\nNCT02759003|Fondazione Salvatore Maugeri|Completed|Mar 2011|Mar 2014|Interventional|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\\r\\nNCT02752659|University of British Columbia|Completed|Jun 2016|Jun 2017|Interventional|Apr 2016|Breast Neoplasms,Lymphedema|\\r\\nNCT02758912|Burnasyan Federal Medical Biophysical Center|Completed|Nov 2016|Oct 2019|Interventional|Apr 2016|Stroke,Angina Pectoris,Infarction,Hemorrhage|\\r\\nNCT02754388|National Taiwan University Hospital|Completed|Feb 2016|Dec 2019|Observational [Patient Registry]|Apr 2016|Lung Neoplasms|\\r\\nNCT02759666|Atridia Pty Ltd.|Completed|Jun 2016|Apr 2019|Interventional|Apr 2016|Neoplasms|\\r\\nNCT02750241|The University of Texas Medical Branch, Galveston|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02752568|Kasr El Aini Hospital|Unknown status|May 2016|Dec 2016|Interventional|Apr 2016||\\r\\nNCT02758015|University of California, San Francisco|Completed|Jun 2016|Mar 2018|Interventional|Apr 2016||Betaine\\r\\nNCT02756884|Arkansas Heart Hospital|Completed|Jun 2015|Jan 2019|Interventional|Apr 2016|Peripheral Arterial Disease,Peripheral Vascular Diseases|\\r\\nNCT02758353|JSI Research & Training Institute, Inc.|Completed|Apr 2015|Nov 2015|Interventional|Apr 2016|Malaria,Stillbirth|\\r\\nNCT02753751|Yale University|Completed|Mar 2018|Jan 2020|Interventional|Apr 2016|Acute Kidney Injury,Wounds and Injuries|\\r\\nNCT02757170|All India In\n\n*** WARNING: max output size exceeded, skipping output. ***\n\nional|Apr 2016||\\r\\nNCT02751047|Seoul National University Hospital|Completed|May 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02758197|Ottawa Hospital Research Institute|Completed|Jul 2016|Oct 2020|Interventional|Apr 2016|Neuralgia,Chronic Pain|\\r\\nNCT02753270|University of Sao Paulo|Completed|Dec 2014|Apr 2017|Interventional|Apr 2016|Varicose Veins|\\r\\nNCT02750839|Azienda Ospedaliera Bolognini di Seriate Bergamo|Unknown status|Apr 2016|Apr 2016|Observational|Apr 2016|Osteoporosis,Fractures,Humeral Fractures|\\r\\nNCT02750488|Bayer|Completed|May 2016|Jul 2016|Interventional|Apr 2016|Dermatitis|\\r\\nNCT02752958|GlaxoSmithKline|Completed|May 2016|Feb 2017|Interventional|Apr 2016|Dentin Sensitivity,Hypersensitivity|Fluorides,Tin Fluorides\\r\\nNCT02753322|The Queen Elizabeth Hospital|Unknown status|Apr 2016|Mar 2018|Interventional|Apr 2016|Stroke|\\r\\nNCT02757261|University of Nove de Julho|Unknown status|Jun 2016|Mar 2017|Interventional|Apr 2016|Bruxism,Sleep Bruxism|Salicylic Acid\\r\\nNCT02754427|University of British Columbia|Completed|Feb 2013|Aug 2015|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02758366|Meyer Children's Hospital|Terminated|Feb 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Astrocytoma,Diffuse Intrinsic Pontine Glioma,Neoplasms|Doxorubicin\\r\\nNCT02755402|Centre hospitalier de l'Université de Montréal (CHUM)|Completed|Jan 2017|May 2021|Interventional|Apr 2016|Hepatitis C|\\r\\nNCT02754453|The Cleveland Clinic|Withdrawn|Jul 2013|Oct 2015|Interventional|Sep 2013|Body Weight,Weight Loss|\\r\\nNCT02755103|Medical University of South Carolina|Active, not recruiting|Jun 2016|Oct 2021|Interventional|Apr 2016|Disease,Substance-Related Disorders,Stress Disorders|\\r\\nNCT02758834|Università Politecnica delle Marche|Completed|Jan 2014|Apr 2016|Observational|Apr 2016|Liver Diseases|\\r\\nNCT02759146|Michigan State University|Completed|May 2016|Nov 2019|Interventional|Apr 2016||\\r\\nNCT02754414|Bloodworks|Unknown status|Apr 2016|Jan 2019|Interventional|Apr 2016||\\r\\nNCT02759783|Royal Marsden NHS Foundation Trust|Active, not recruiting|Nov 2016|Oct 2024|Interventional|Apr 2016|Carcinoma|\\r\\nNCT02756923|Weill Medical College of Cornell University|Suspended|Apr 2012|Dec 2025|Observational|Apr 2016|Infertility|\\r\\nNCT02759237|Medtronic Cardiovascular|Terminated|Feb 2016|May 2017|Observational|Apr 2016|Aortic Valve Stenosis|\\r\\nNCT02757391|M.D. Anderson Cancer Center|Terminated|Aug 2019|Oct 2020|Interventional|Apr 2016|Carcinoma,Colorectal Neoplasms,Adenocarcinoma,Stomach Neoplasms,Esophageal Neoplasms,Cholangiocarcinoma|Aldesleukin,Cyclophosphamide,Pembrolizumab,Interleukin-2,Immunologic Factors\\r\\nNCT02750904|Fred Hutchinson Cancer Research Center|Completed|Apr 2017|May 2019|Interventional|Mar 2016|Disease,Bipolar Disorder|Nicotine\\r\\nNCT02758418|Universitat Jaume I|Unknown status|Apr 2016|Jul 2019|Interventional|Apr 2016|Adjustment Disorders|\\r\\nNCT02756039|AstraZeneca|Completed|May 2016|Aug 2018|Observational|Apr 2016||\\r\\nNCT02755077|Massachusetts General Hospital|Completed|Jul 2014|Jan 2016|Interventional|Apr 2016||\\r\\nNCT02751801|Sheffield Teaching Hospitals NHS Foundation Trust|Completed|Nov 2016|Dec 2017|Observational|Apr 2016|Hypophosphatasia|\\r\\nNCT02751177|Institut de Cancérologie de Lorraine|Completed|Mar 2016|May 2017|Interventional|Mar 2016|Colorectal Neoplasms|\\r\\nNCT02758574|University of Pittsburgh|Completed|May 2016|Aug 2021|Interventional|Mar 2016|Pulmonary Embolism,Embolism|\\r\\nNCT02758587|NHS Greater Glasgow and Clyde|Recruiting|Jul 2017|Dec 2021|Interventional|Apr 2016|Mesothelioma,Carcinoma,Pancreatic Neoplasms|Pembrolizumab\\r\\nNCT02752100|Third Military Medical University|Unknown status|Mar 2016|May 2020|Interventional|Mar 2016|Arterial Occlusive Diseases|\\r\\nNCT02755818|University of California, Davis|Terminated|Oct 2008|Feb 2019|Observational|Mar 2016|Insulin Resistance|Heparin,Calcium heparin\\r\\nNCT02752906|Sanofi Pasteur, a Sanofi Company|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Meningococcal Infections,Meningitis|Vaccines\\r\\nNCT02750371|University Hospital, Bordeaux|Active, not recruiting|Jul 2016|Oct 2021|Interventional|Apr 2016|Adenoma,Meningioma,Pituitary Neoplasms,Pituitary Diseases|\\r\\nNCT02751125|University of Bergen|Completed|Jun 2014|Mar 2020|Interventional|Mar 2016|Atrophy|\\r\\nNCT02754700|High Point University|Completed|Apr 2016|Feb 2019|Interventional|Apr 2016|Knee Injuries|\\r\\nNCT02756442|Assistance Publique Hopitaux De Marseille|Unknown status|Apr 2016|Apr 2019|Interventional|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Diabetes|\\r\\nNCT02756637|Abramson Cancer Center of the University of Pennsylvania|Completed|Apr 2016|Nov 2016|Observational|Apr 2016|Urinary Bladder Neoplasms|\\r\\nNCT02755688|Royal Brompton & Harefield NHS Foundation Trust|Unknown status|Jun 2015|Mar 2020|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02753387|Rennes University Hospital|Completed|May 2016|Sep 2018|Interventional|Apr 2016|Bacterial Infections,Head and Neck Neoplasms|Chlorhexidine\\r\\nNCT02758470|University of British Columbia|Completed|Nov 2016|Jun 2017|Interventional|Apr 2016|Fatigue,Hypoxia|Acetazolamide,Methazolamide\\r\\nNCT02754375|Centre Hospitalier Universitaire de Nice|Unknown status|May 2016|May 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\\r\\nNCT02758756|University of Rochester|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Fatigue|\\r\\nNCT02750787|Abbott Nutrition|Completed|Aug 2016|Jul 2017|Interventional|Apr 2016|Malabsorption Syndromes|\\r\\nNCT02757339|Mclean Hospital|Enrolling by invitation|Jun 2015|May 2022|Observational|Mar 2016|Disease,Stress Disorders,Dissociative Disorders,Dissociative Identity Disorder|\\r\\nNCT02753959|Guy's and St Thomas' NHS Foundation Trust|Completed|Aug 2016|Sep 2019|Interventional|Apr 2016|Neuromuscular Diseases|\\r\\nNCT02753426|University of California, San Francisco|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Kidney Diseases,Renal Insufficiency,Cardio-Renal Syndrome|Doxycycline\\r\\nNCT02757183|AnalyticsPlus, Inc.|Unknown status|Apr 2016|Mar 2017|Observational|Apr 2016||\\r\\nNCT02750293|University of Tromso|Completed|Jun 2015|Sep 2017|Interventional|Apr 2016|Vitamin D Deficiency|Cholecalciferol\\r\\nNCT02757274|European Association of Urology Research Foundation|Recruiting|Feb 2017|Jul 2027|Observational [Patient Registry]|Apr 2016|Urinary Incontinence,Enuresis|\\r\\nNCT02756741|All India Institute of Medical Sciences, New Delhi|Completed|Apr 2014|Jul 2015|Interventional|Apr 2016|Peritonitis,Fibrosis|\\r\\nNCT02758964|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2019|Observational|Apr 2016|Intracranial Embolism,Embolism,Aortic Valve Stenosis|\\r\\nNCT02753439|The Baruch Padeh Medical Center, Poriya|Unknown status|Feb 2017|Feb 2019|Interventional|Mar 2016|Tooth|\\r\\nNCT02751281|Isfahan University of Medical Sciences|Completed|Dec 2014|Apr 2016|Interventional|Apr 2016|Kidney Calculi,Nephrolithiasis|\\r\\nNCT02756676|Ospedale Generale Di Zona Moriggia-Pelascini|Completed|Apr 2015|Dec 2016|Interventional|Apr 2016|Parkinson Disease|\\r\\nNCT02750215|Massachusetts General Hospital|Completed|May 2016|May 2021|Interventional|Apr 2016|Lung Neoplasms|\\r\\nNCT02755935|Cochlear|Completed|May 2016|Sep 2017|Interventional|Apr 2016|Hearing Loss|\\r\\nNCT02759523|Penn State University|Completed|Jul 2013|Dec 2015|Observational|Apr 2016|Pediatric Obesity|\\r\\nNCT02756533|University Hospital, Grenoble|Recruiting|Aug 2016|Aug 2021|Interventional|Mar 2016|Lung Diseases,Pulmonary Disease,Signs and Symptoms|\\r\\nNCT02752841|Brown University|Terminated|May 2016|May 2019|Interventional|Apr 2016|Kidney Calculi,Calculi|Vitamin D\\r\\nNCT02758392|Janssen Research & Development, LLC|Completed|Apr 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02755870|Clene Nanomedicine|Completed|Apr 2015|Oct 2016|Interventional|Apr 2016||\\r\\nNCT02752464|Boston Medical Center|Completed|Sep 2016|Jun 2018|Interventional|Apr 2016||\\r\\nNCT02756780|Royal Marsden NHS Foundation Trust|Unknown status|Apr 2016|Apr 2018|Interventional|Apr 2016||\\r\\nNCT02753998|Assistance Publique - Hôpitaux de Paris|Active, not recruiting|Dec 2016|Sep 2021|Interventional|Apr 2016|Arteriovenous Fistula,Constriction,Fistula|Paclitaxel\\r\\nNCT02751307|Taipei Medical University WanFang Hospital|Completed|May 2013|Jan 2015|Interventional|Apr 2016|Congenital Abnormalities,Metabolic Syndrome,Schizophrenia|Metformin,Clozapine\\r\\nNCT02757755|Armata Pharmaceuticals, Inc.|Completed|May 2016|Aug 2016|Interventional|Apr 2016||\\r\\nNCT02753972|University of New Mexico|Completed|Aug 2006|Jan 2008|Interventional|Apr 2016||\\r\\nNCT02751853|University of Luebeck|Unknown status|Dec 2016|Aug 2020|Interventional|Apr 2016|Heart Failure|\\r\\nNCT02752971|Hospital Central Dr. Luis Ortega|Completed|Feb 2015||Interventional|Mar 2016|Pain|Diclofenac,Bupivacaine\\r\\nNCT02755012|McGill University|Completed|Jun 2012|Nov 2013|Observational|Apr 2016|Infections,Mastitis,Malnutrition,Infant Nutrition Disorders,Growth Disorders,Stress|\\r\\nNCT02751996|F-star Therapeutics, Inc.|Completed|May 2016|Feb 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis B,Hepatitis|Tenofovir\\r\\nNCT02752893|Dartmouth-Hitchcock Medical Center|Completed|Jan 2017|Apr 2019|Observational|Apr 2016|Breast Neoplasms|\\r\\nNCT02753842|Global Protection Corp.|Completed|May 2016|Jul 2017|Interventional|Apr 2016||\\r\\nNCT02757040|Peking University People's Hospital|Unknown status|Dec 2016|Dec 2018|Interventional|Apr 2016|Leukemia|Arsenic Trioxide\\r\\nNCT02751606|Radboud University|Unknown status|Jun 2015|Nov 2019|Interventional|Nov 2014|Neoplasms,Breast Neoplasms,Rectal Neoplasms|\\r\\nNCT02751372|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016||\\r\\nNCT02753764|National Jewish Health|Completed|Jan 2017|Feb 2019|Interventional|Apr 2016|Asthma|Prednisone,AZD7624\\r\\nNCT02758938|University of Wisconsin, Madison|Completed|Jun 2016|Sep 2018|Interventional|Dec 2015|Lower Urinary Tract Symptoms|\\r\\nNCT02752399|Federal University of São Paulo|Unknown status|Apr 2016|Jun 2017|Observational|Apr 2016|Hypertension,Heart Defects,Eisenmenger Complex|\\r\\nNCT02753296|University of Sheffield|Unknown status|May 2016|Jun 2018|Observational|Apr 2016||\\r\\nNCT02759432|Teesside University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02750137|KK Women's and Children's Hospital|Completed|Aug 2014|May 2015|Observational|Apr 2016|Drug-Related Side Effects and Adverse Reactions|Tetracaine\\r\\nNCT02754466|University of Brasilia|Terminated|May 2017|Sep 2021|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02752191|Paul Finn|Recruiting|Apr 2016|Apr 2021|Interventional|Apr 2016|Heart Diseases,Heart Defects|Ferrosoferric Oxide\\r\\nNCT02753517|University Hospital, Lille|Recruiting|Dec 2015|Nov 2023|Interventional|Apr 2016|Liver Failure,Hepatic Insufficiency|\\r\\nNCT02758054|University of Texas Southwestern Medical Center|Active, not recruiting|Jun 2017|Mar 2023|Interventional|Apr 2016|Carcinoma|\\r\\nNCT02757573|Tampere University Hospital|Active, not recruiting|Apr 2016|Dec 2022|Interventional|Apr 2016|Hypercapnia|\\r\\nNCT02752789|National Institute of Allergy and Infectious Diseases (NIAID)|Completed|Jul 2014|Nov 2019|Observational|Apr 2016||\\r\\nNCT02756416|University of Nottingham|Unknown status|Jul 2016|May 2017|Interventional|Mar 2016|Syndrome|\\r\\nNCT02758106|Chung Shan Medical University|Completed|Feb 2014|Nov 2015|Interventional|Apr 2016|Respiratory Insufficiency|\\r\\nNCT02759159|Xuanwu Hospital, Beijing|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Alzheimer Disease|\\r\\nNCT02753777|University of Pennsylvania|Recruiting|Apr 2016|Dec 2025|Observational [Patient Registry]|Apr 2016|Pemphigoid,Pemphigus|\\r\\nNCT02754245|Baylor Research Institute|Unknown status|Nov 2016|Jul 2017|Observational|Apr 2016|Emergencies|\\r\\nNCT02754687|Health Decisions|Unknown status|Apr 2016|Jan 2020|Interventional|Mar 2016||Nandrolone Decanoate,Nandrolone,Nandrolone phenpropionate\\r\\nNCT02755337|Dr. Soetomo General Hospital|Unknown status|Jan 2016|Dec 2016|Observational|Apr 2016|Lung Neoplasms|\\r\\nNCT02755090|University of New Mexico|Completed|Jul 2016|May 2017|Interventional|Apr 2016||Nitrous Oxide\\r\\nNCT02751437|Liverpool Women's NHS Foundation Trust|Completed|Aug 2016|Mar 2018|Interventional|Mar 2016|Premature Birth|\\r\\nNCT02757950|GlaxoSmithKline|Completed|Jul 2016|May 2017|Observational|Apr 2016|Diphtheria|\\r\\nNCT02756754|University Hospital, Toulouse|Completed|Nov 2016|May 2019|Interventional|Apr 2016|Adenoma,Adrenocortical Adenoma,Hyperaldosteronism|\\r\\nNCT02754726|HonorHealth Research Institute|Active, not recruiting|Apr 2016|Jun 2022|Interventional|Apr 2016|Adenocarcinoma|Gemcitabine,Paclitaxel,Nivolumab,Albumin-Bound Paclitaxel\\r\\nNCT02759549|Emory University|Withdrawn|Sep 2015||Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02755714|Haukeland University Hospital|Completed|Jun 2016|Oct 2020|Interventional|Apr 2016||Bromides,Ipratropium\\r\\nNCT02750358|Memorial Sloan Kettering Cancer Center|Active, not recruiting|May 2016|May 2022|Interventional|Apr 2016|Breast Neoplasms,Triple Negative Breast Neoplasms|\\r\\nNCT02754921|Mohamed Sayed Mohamed Abbas|Completed|Jan 2013||Interventional|Apr 2016||\\r\\nNCT02755259|University of Zurich|Completed|Jan 2017|Apr 2019|Interventional|Mar 2016|Hypertension|Acetazolamide\\r\\nNCT02759081|Dalin Tzu Chi General Hospital|Completed|Jan 2015||Interventional|Apr 2016||\\r\\nNCT02755155|University Hospital, Strasbourg, France|Terminated|Sep 2016|Aug 2019|Interventional|Apr 2016|Hypoalbuminemia,Syndrome,Systemic Inflammatory Response Syndrome|\\r\\nNCT02758119|Ilumens|Completed|Jun 2016|Oct 2016|Interventional|Apr 2016|Heart Arrest,Out-of-Hospital Cardiac Arrest|\\r\\nNCT02755415|China Medical University Hospital|Unknown status|May 2016|Dec 2017|Interventional|Apr 2016|Stroke|\\r\\nNCT02751268|Armed Forces Hampyeong Hospital|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Psychomotor Agitation,Emergence Delirium|Ropivacaine\\r\\nNCT02756572|University of Washington|Completed|Sep 2016|Jul 2020|Interventional|Apr 2016|Leukemia,Neoplasms,Preleukemia,Myelodysplastic Syndromes,Anemia,Syndrome|Cytarabine,Cyclosporine,Mycophenolic Acid,Sirolimus,Fludarabine,Fludarabine phosphate,Melphalan,Mechlorethamine,Mitoxantrone,Nitrogen Mustard Compounds,Cladribine,2-chloro-3-deoxyadenosine,Cyclosporins,Lenograstim\\r\\nNCT02756871|Institute of Child Health|Completed|Jul 2015|Feb 2017|Interventional|Apr 2016||\\r\\nNCT02750618|Ultragenyx Pharmaceutical Inc|Completed|May 2016|Sep 2019|Interventional|Dec 2015|Familial Hypophosphatemic Rickets,Hypophosphatemia|\\r\\nNCT02757196|Peking University People's Hospital|Unknown status|May 2016|Dec 2018|Interventional|Apr 2016|Thrombocytopenia,Purpura|Methylprednisolone,Methylprednisolone Acetate,Methylprednisolone Hemisuccinate,Prednisolone,Prednisolone acetate,Rituximab,Prednisolone hemisuccinate,Prednisolone phosphate\\r\\nNCT02758093|University of Alabama at Birmingham|Completed|Sep 2016|Mar 2020|Interventional|Mar 2016||\\r\\nNCT02750943|GlaxoSmithKline|Completed|Nov 2015|Mar 2016|Interventional|Nov 2015|Gingivitis|Fluorides,Tin Fluorides,Fluorophosphate\\r\\nNCT02754908|The University of Hong Kong|Completed|Jan 2016|Jun 2018|Interventional|Apr 2016|Brain Neoplasms|\\r\\nNCT02750514|Bristol-Myers Squibb|Terminated|May 2016|Jan 2020|Interventional|Apr 2016|Carcinoma|Nivolumab,Ipilimumab,Dasatinib,Linrodostat\\r\\nNCT02755350|LVCT Health|Unknown status|Aug 2015|Apr 2017|Interventional|Nov 2015||Emtricitabine\\r\\nNCT02753374|Beijing Children's Hospital|Not yet recruiting|May 2016|Jul 2030|Observational|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02759419|Bayer|Recruiting|Jun 2016|Dec 2023|Interventional|Apr 2016|Pulmonary Arterial Hypertension,Hypertension|Riociguat\\r\\nNCT02757612|Universidad de Murcia|Completed|Jun 2015|Jul 2016|Interventional|Apr 2016|Burning Mouth Syndrome,Syndrome,Burns|\\r\\nNCT02754297|CHU de Quebec-Universite Laval|Recruiting|Apr 2016|Dec 2026|Interventional|Mar 2016|Neoplasms,Neuroendocrine Tumors,Carcinoid Tumor,Carcinoma|Lutetium Lu 177 dotatate\\r\\nNCT02758665|University of Ulm|Active, not recruiting|Sep 2016|Mar 2022|Interventional|Apr 2016|Leukemia|Venetoclax,Obinutuzumab\\r\\nNCT02755285|Fujifilm Medical Systems USA, Inc.|Completed|Aug 2016|Oct 2016|Interventional|Apr 2016||\\r\\nNCT02757690|Asan Medical Center|Completed|Jan 2015|Feb 2016|Interventional|Apr 2016|Neoplasms,Brain Neoplasms|\\r\\nNCT02753218|LEO Pharma|Terminated|Apr 2016|May 2016|Interventional|Apr 2016|Psoriasis|Midazolam\\r\\nNCT02754986|University of Hyogo|Completed|Mar 2015||Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency|\\r\\nNCT02752048|Taiho Pharmaceutical Co., Ltd.|Completed|May 2016|Oct 2017|Interventional|Apr 2016|Muscular Dystrophies,Muscular Dystrophy|\\r\\nNCT02752256|University of Iowa|Completed|Oct 2015|Oct 2017|Observational|Apr 2016||Plasminogen,Tissue Plasminogen Activator\\r\\nNCT02756936|Genuine Research Center, Egypt|Completed|Feb 2016|Mar 2016|Interventional|Apr 2016||\\r\\nNCT02756000|Clinical Hospital Center Zemun|Unknown status|Jan 2016|Jul 2018|Interventional|Apr 2016|Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Infarction|Dobutamine\\r\\nNCT02754492|Terumo BCT|Completed|Apr 2016|Feb 2017|Interventional|Apr 2016||\\r\\nNCT02757677|Swiss Vision Network|Unknown status|Dec 2015|Dec 2019|Observational|Apr 2016|Glaucoma|\\r\\nNCT02752373|Brain Sentinel|Terminated|May 2016|Feb 2017|Observational|Mar 2016|Epilepsy,Seizures|\\r\\nNCT02752230|Kettering Health Network|Withdrawn|Nov 2016|Jun 2021|Interventional|Mar 2016|Pain|\\r\\nNCT02756728|BioInvent International AB|Terminated|May 2016|Dec 2016|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Melphalan\\r\\nNCT02751658|University Hospital, Montpellier|Completed|Nov 2016|Jul 2019|Interventional|Mar 2016|Otorhinolaryngologic Diseases|\\r\\nNCT02754518|University of Chicago|Completed|Apr 2016|Apr 2019|Interventional|Apr 2016|Heart Failure|Valsartan,Sacubitril and valsartan sodium hydrate drug combination\\r\\nNCT02759380|Sahlgrenska University Hospital, Sweden|Recruiting|Mar 2016|Oct 2022|Interventional|Apr 2016|Prostatic Neoplasms|Phytoestrogens\\r\\nNCT02755649|Regeneron Pharmaceuticals|Completed|Jan 2016|Mar 2017|Interventional|Mar 2016|Dermatitis,Eczema|\\r\\nNCT02751827|Institut Bergonié|Completed|Feb 2016|Nov 2019|Observational|Apr 2016||\\r\\nNCT02755545|Galderma Laboratories, L.P.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Acne Vulgaris|Salicylic Acid,Adapalene,Salicylates\\r\\nNCT02750345|Cycle Pharmaceuticals Ltd.|Completed|Mar 2016|May 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02755532|Federal University of São Paulo|Completed|Jan 2014|Oct 2015|Interventional|Apr 2016||Bupivacaine\\r\\nNCT02758743|Biohit Oyj|Completed|Apr 2016|May 2017|Interventional|Apr 2016||\\r\\nNCT02754947|Nationwide Children's Hospital|Completed|Feb 2015|Mar 2016|Observational|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Nervous System Diseases,Cardiovascular Diseases|\\r\\nNCT02750280|Calvary Hospital, Bronx, NY|Completed|Jun 2015|Dec 2015|Interventional|Apr 2016|Diabetic Foot,Foot Ulcer,Ulcer|\\r\\nNCT02756325|NYU Langone Health|Withdrawn|Jun 2016|Jan 2019|Interventional|Apr 2016|Infertility|\\r\\nNCT02758717|Academic and Community Cancer Research United|Active, not recruiting|May 2016|May 2024|Interventional|Apr 2016|Lymphoma,Hodgkin Disease|Antineoplastic Agents,Nivolumab,Brentuximab Vedotin,Antibodies,Immunoglobulins,Immunoconjugates\\r\\nNCT02751034|Medy-Tox|Completed|Jun 2013|Jan 2014|Interventional|Apr 2015||Lidocaine\\r\\nNCT02751476|Action Contre la Faim|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Malnutrition,Severe Acute Malnutrition,Protein-Energy Malnutrition|Disinfectants\\r\\nNCT02755454|University Health Network, Toronto|Completed|Oct 2013|Nov 2018|Interventional|Mar 2016|Lung Neoplasms|\\r\\nNCT02752867|Dongfang Hospital Beijing University of Chinese Medicine|Unknown status|Dec 2016|Nov 2019|Interventional|Mar 2016|Cerebral Infarction,Infarction,Cognitive Dysfunction|\\r\\nNCT02754830|Eli Lilly and Company|Completed|Apr 2016|Jul 2018|Interventional|Apr 2016|Alzheimer Disease|\\r\\nNCT02753738|Medical University of Vienna|Unknown status|Aug 2016||Interventional|Apr 2016||Citalopram\\r\\nNCT02750267|University of Virginia|Completed|May 2016|May 2016|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02754999|Prolong Pharmaceuticals|Completed|Mar 2016|May 2017|Interventional|Apr 2016|Anemia|\\r\\nNCT02754843|Sonova AG|Completed|Oct 2015||Interventional|Oct 2015|Hearing Loss|\\r\\nNCT02759055|HealthPartners Institute|Completed|Oct 2016|Dec 2019|Interventional|Apr 2016|Prediabetic State,Glucose Intolerance|\\r\\nNCT02753673|Memorial Sloan Kettering Cancer Center|Completed|Apr 2016|Apr 2020|Observational|Apr 2016||\\r\\nNCT02754531|Indonesia University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02750033|Seton Healthcare Family|Withdrawn|Oct 2016|Mar 2017|Observational|Apr 2016|Carcinoma|\\r\\nNCT02759133|Centre Antoine Lacassagne|Recruiting|Jun 2016|Nov 2022|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02756650|Novartis Pharmaceuticals|Completed|Jun 2016|Jan 2019|Interventional|Mar 2016|Behcet Syndrome|\\r\\nNCT02752152|Institut de Recherche pour le Developpement|Completed|Dec 2015|Oct 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis B,Syphilis,Hepatitis|\\r\\nNCT02751385|Boehringer Ingelheim|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Carcinoma|Nintedanib,Ethinyl estradiol,Ethinyl Estradiol-Norgestrel Combination\\r\\nNCT02751879|Boehringer Ingelheim|Completed|Nov 2016|Sep 2017|Observational|Apr 2016|Carcinoma|\\r\\nNCT02756663|Novartis Pharmaceuticals|Withdrawn|Dec 2016|Feb 2021|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Dexamethasone,Panobinostat\\r\\nNCT02756273|Centre Hospitalier Universitaire, Amiens|Recruiting|May 2016|May 2022|Interventional|Apr 2016||\\r\\nNCT02755974|Imperial College London|Unknown status|Jan 2009|Apr 2021|Observational|Apr 2016|Lung Diseases,Pulmonary Disease|\\r\\nNCT02756507|Babes-Bolyai University|Completed|Jun 2016|Jun 2018|Interventional|Apr 2016|Disease,Depression,Anxiety Disorders,Panic Disorder|\\r\\nNCT02750553|Jiangsu HengRui Medicine Co., Ltd.|Completed|Jan 2015||Interventional|Apr 2016||\\r\\nNCT02750228|Mednax Center for Research, Education, Quality and Safety|Completed|May 2016|Jun 2020|Observational|Mar 2016|Ductus Arteriosus|\\r\\nNCT02751710|Ontario Clinical Oncology Group (OCOG)|Recruiting|Dec 2016|Dec 2022|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02753361|Suez Canal University|Completed|May 2016|Dec 2016|Interventional|Apr 2016|Lipoma|\\r\\nNCT02753634|Lawson Health Research Institute|Completed|Apr 2015|Jun 2016|Interventional|Mar 2016|Osteoarthritis|\\r\\nNCT02759250|argenx|Completed|Feb 2015|Jun 2018|Interventional|Apr 2016|Nasopharyngeal Carcinoma|\\r\\nNCT02757482|Celal Bayar University|Completed|Sep 2014|Jun 2015|Interventional|Apr 2016||\\r\\nNCT02757105|RedHill Biopharma Limited|Completed|May 2016|Jul 2017|Interventional|Apr 2016|Irritable Bowel Syndrome,Syndrome,Diarrhea|Ondansetron\\r\\nNCT02756520|Fresenius Kabi|Completed|Sep 2016|Oct 2018|Observational|Apr 2016|Kidney Diseases,Renal Insufficiency|\\r\\nNCT02753309|The University of Texas Health Science Center at San Antonio|Completed|Jun 2016|Mar 2021|Interventional|Apr 2016|Urinary Bladder Neoplasms|Sirolimus\\r\\nNCT02756832|Takeda|Completed|Sep 2016|Apr 2018|Observational|Apr 2016|Diabetes Mellitus|Alogliptin\\r\\nNCT02758158|University Health Network, Toronto|Completed|Jan 2016|Feb 2017|Interventional|Mar 2016|Thyroid Neoplasms,Thyroid Nodule,Thyroid Diseases|\\r\\nNCT02752360|Beijing Friendship Hospital|Unknown status|Apr 2016|Dec 2018|Interventional|Apr 2016|Colonic Neoplasms,Crohn Disease,Diverticulum,Diverticular Diseases,Diverticulosis|\\r\\nNCT02757794|Assistance Publique Hopitaux De Marseille|Recruiting|Nov 2016|Jun 2022|Interventional|Apr 2016|Memory Disorders|\\r\\nNCT02751346|Washington University School of Medicine|Completed|Jan 2016|Feb 2017|Observational|Apr 2016|Pain|\\r\\nNCT02757027|Konkuk University Medical Center|Unknown status|May 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02756689|University of Alabama at Birmingham|Completed|Mar 2016|Oct 2017|Interventional|Apr 2016||\\r\\nNCT02751164|Intensive Care National Audit & Research Centre|Completed|Apr 2013|May 2016|Observational|Apr 2016|Critical Illness|\\r\\nNCT02754765|Médecins Sans Frontières, France|Recruiting|Dec 2016|Aug 2023|Interventional|Apr 2016|Tuberculosis,Bacterial Infections|Moxifloxacin,Levofloxacin,Ofloxacin,Linezolid,Pyrazinamide,Bedaquiline,Clofazimine\\r\\nNCT02757729|Amorepacific Corporation|Completed|Oct 2015||Interventional|Apr 2016|Dermatitis,Eczema|\\r\\nNCT02751866|University of Cincinnati|Recruiting|Jan 2016|Jul 2023|Interventional|Apr 2016|Overweight,Hyperphagia|\\r\\nNCT02759068|Hospices Civils de Lyon|Completed|Nov 2014|May 2017|Interventional|Apr 2016|Consciousness Disorders|\\r\\nNCT02752503|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Un\"","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["[Truncated to first 65536 bytes]\nOut[5]: \"Id|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions\\r\\nNCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||\\r\\nNCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|\\r\\nNCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|\\r\\nNCT02758860|University of Roma La Sapienza|Active, not recruiting|Jun 2016|Sep 2020|Observational [Patient Registry]|Apr 2016|Diverticular Diseases,Diverticulum,Diverticulosis|\\r\\nNCT02757209|Consorzio Futuro in Ricerca|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate\\r\\nNCT02752438|Ankara University|Unknown status|May 2016|Jul 2017|Observational [Patient Registry]|Apr 2016|Hypoventilation|\\r\\nNCT02753543|Ruijin Hospital|Unknown status|Nov 2015|Nov 2019|Interventional|Apr 2016|Lymphoma|\\r\\nNCT02757508|Washington University School of Medicine|Completed|Mar 2016|Jul 2017|Interventional|Apr 2016||Vitamins\\r\\nNCT02753530|Orphazyme|Completed|Aug 2017|Jan 2021|Interventional|Apr 2016|Myositis|\\r\\nNCT02754817|Novo Nordisk A/S|Completed|Apr 2016|Oct 2016|Observational|Apr 2016|Diabetes Mellitus|Liraglutide,Xultophy\\r\\nNCT02759276|Daniel Alexandre Bottino|Completed|May 2015|Dec 2015|Observational|Apr 2016|Hypertension|\\r\\nNCT02750956|Bulent Ecevit University|Completed|Jun 2015|Mar 2016|Observational|Apr 2016|Periodontal Diseases|\\r\\nNCT02752113|Institut für Pharmakologie und Präventive Medizin|Completed|Apr 2016|May 2019|Interventional|Apr 2016|Diabetes Mellitus|Metformin,Empagliflozin,Linagliptin\\r\\nNCT02752698|The Third Xiangya Hospital of Central South University|Active, not recruiting|Jan 2015|Dec 2021|Interventional|Jun 2015|Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones|\\r\\nNCT02755779|Tel Aviv Medical Center|Unknown status|Jun 2016|Jun 2017|Observational|Apr 2016||\\r\\nNCT02750384|Medicines for Malaria Venture|Terminated|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02754609|James Cook University, Queensland, Australia|Completed|Sep 2016|Oct 2019|Interventional|Apr 2016|Hookworm Infections,Celiac Disease|\\r\\nNCT02755701|Soonchunhyang University Hospital|Unknown status|Jul 2016|Dec 2018|Interventional|Apr 2016|Ascites|\\r\\nNCT02751762|Member Companies of the Opioid PMR Consortium|Recruiting|Nov 2017|Oct 2022|Observational|Apr 2016|Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior|\\r\\nNCT02756299|Marmara University|Completed|Jun 2014|Apr 2015|Interventional|Apr 2016|Sleep Apnea Syndromes,Sleep Apnea|\\r\\nNCT02750709|Cycle Pharmaceuticals Ltd.|Completed|Oct 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02753907|Yonsei University|Completed|Jun 2015||Interventional|Apr 2016||\\r\\nNCT02755467|Cutera Inc.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Hemangioma|\\r\\nNCT02755298|University of Zurich|Completed|Oct 2016|Nov 2020|Interventional|Mar 2016|Hypertension|Acetazolamide\\r\\nNCT02759614|Guangdong Association of Clinical Trials|Unknown status|Apr 2016|Jun 2019|Interventional|Mar 2016|Carcinoma|Bevacizumab,Erlotinib Hydrochloride\\r\\nNCT02752815|Ruijin Hospital|Unknown status|Apr 2016|Jun 2020|Interventional|Apr 2016|Lymphoma|Prednisone,Cyclophosphamide,Rituximab,Vincristine,Epirubicin\\r\\nNCT02757131|The Cleveland Clinic|Completed|Jul 2016|Jul 2017|Interventional|Apr 2016|Iatrogenic Disease|\\r\\nNCT02758704|St. Justine's Hospital|Completed|Oct 2015|Jun 2021|Interventional|Apr 2016||\\r\\nNCT02750501|Alcresta Therapeutics, Inc.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02759913|Iron Horse Diagnostics, Inc.|Unknown status|Jan 2015|Dec 2016|Observational|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\\r\\nNCT02752724|VA Puget Sound Health Care System|Completed|Mar 2016|Apr 2018|Interventional|Mar 2016|Depressive Disorder,Depression|Ketamine,Methohexital\\r\\nNCT02758444|University of Colorado, Denver|Completed|Nov 2015|Feb 2019|Interventional|Apr 2016||Micronutrients,Trace Elements\\r\\nNCT02758067|H. Lundbeck A/S|Withdrawn|Jun 2016||Interventional|Apr 2016|Schizophrenia|Risperidone,Brexpiprazole\\r\\nNCT02759341|Ospedale San Giovanni Bellinzona|Completed|Feb 2016|Nov 2017|Interventional|Apr 2016|Myocardial Infarction,Cardiomyopathies,Microvascular Angina,Takotsubo Cardiomyopathy,Syndrome,Infarction|\\r\\nNCT02753803|Dong-A ST Co., Ltd.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016||Pioglitazone\\r\\nNCT02752490|The University of Texas Health Science Center, Houston|Completed|Apr 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02759562|Gilead Sciences|Terminated|Nov 2016|Jul 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02758262|Laval University|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016|Hyperphagia|\\r\\nNCT02754258|Children's Hospital of Eastern Ontario|Unknown status|Jan 2017|Dec 2018|Interventional|Apr 2016||Methylphenidate\\r\\nNCT02755207|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Apr 2016|Dec 2020|Observational|Mar 2016|Acute Coronary Syndrome,Syndrome|\\r\\nNCT02759900|The Skin Center Dermatology Group|Recruiting|Jan 2016|Jan 2023|Interventional|Apr 2016|Molluscum Contagiosum,Keratosis,Bowens Disease,Rosacea,Skin Diseases|\\r\\nNCT02752581|Mert Özcan|Completed|Jan 2009|Apr 2013|Interventional|Apr 2016|Hemarthrosis|\\r\\nNCT02759796|Instituto de Investigación Hospital Universitario La Paz|Completed|Nov 2015|Apr 2017|Interventional|Apr 2016|Necrosis,Neovascularization,Fat Necrosis|\\r\\nNCT02754063|University Hospital, Grenoble|Active, not recruiting|Jun 2016|Apr 2022|Interventional|Apr 2016|Brain Injuries,Wounds and Injuries|3\\r\\nNCT02750917|Foisor Orthopedics Clinical Hospital|Completed|Sep 2014|Mar 2015|Interventional|Feb 2016|Pain|Etoricoxib,Lornoxicam\\r\\nNCT02753569|Institute of Cancer Research, United Kingdom|Completed|May 2016|May 2020|Observational|Apr 2016||\\r\\nNCT02751255|VU University Medical Center|Active, not recruiting|Jul 2016|Mar 2022|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Tretinoin\\r\\nNCT02751528|NantBioScience, Inc.|Unknown status|Dec 2016|Dec 2020|Interventional|Apr 2016|Breast Neoplasms|Vaccines\\r\\nNCT02751619|University of Campania Luigi Vanvitelli|Completed|Jan 2013|Dec 2015|Interventional|Apr 2016|Pain|Lidocaine\\r\\nNCT02757833|Lawson Health Research Institute|Withdrawn|Feb 2019|Feb 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\\r\\nNCT02750761|Merck Sharp & Dohme Corp.|Completed|May 2016|Dec 2018|Interventional|Apr 2016|Infections,Bacterial Infections,Gram-Positive Bacterial Infections|Tedizolid phosphate,Tedizolid,Oxazolidinones\\r\\nNCT02752594|Sharda University|Completed|Apr 2015|Apr 2015|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02753452|Holland Bloorview Kids Rehabilitation Hospital|Unknown status|May 2015|Mar 2020|Interventional|Apr 2016||\\r\\nNCT02752763|Niğde State Hospital|Completed|Oct 2015|Mar 2016|Interventional|Mar 2016|Dry Eye Syndromes,Keratoconjunctivitis Sicca|Dextrans,Povidone,Ophthalmic Solutions,Lubricant Eye Drops\\r\\nNCT02753816|Spectrum Health Hospitals|Terminated|Apr 2016|Dec 2019|Interventional|Apr 2016|Burns|Tranexamic Acid\\r\\nNCT02751294|GlaxoSmithKline|Completed|May 2016|Aug 2016|Interventional|Apr 2016|Malaria|Tafenoquine\\r\\nNCT02756429|Hospices Civils de Lyon|Completed|Feb 2014|Jan 2018|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02750163|Università Politecnica delle Marche|Completed|Jul 2017|Jun 2019|Observational|Apr 2016|Shock|Acetaminophen\\r\\nNCT02751905|Biogen|Completed|Apr 2016|May 2016|Interventional|Apr 2016|Neuralgia|\\r\\nNCT02753153|University of Liege|Completed|May 2011|May 2015|Interventional|Apr 2016|Tooth Loss|\\r\\nNCT02750891|Sumitomo Dainippon Pharma Co., Ltd.|Completed|Apr 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Diffuse Intrinsic Pontine Glioma|\\r\\nNCT02751073|Mayo Clinic|Completed|Feb 2016|Jul 2018|Observational|Feb 2016|Infections,Communicable Diseases,Urinary Tract Infections,Prolapse,Pelvic Organ Prolapse|\\r\\nNCT02753114|University of British Columbia|Completed|Nov 2017|May 2018|Interventional|Apr 2016|Acute Pain|Ketamine\\r\\nNCT02752516|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016||\\r\\nNCT02752269|Medical University of Graz|Completed|Oct 2014|Jun 2019|Observational|Nov 2015|Sjogrens Syndrome,Hypertension,Vascular Diseases,Syndrome|\\r\\nNCT02754713|Hippocration General Hospital|Recruiting|Sep 2009|Dec 2025|Observational|Apr 2016|Pericarditis|\\r\\nNCT02759770|Beijing Anzhen Hospital|Completed|Jul 2017|Sep 2017|Observational|Apr 2016|Respiratory Distress Syndrome,Acute Lung Injury|\\r\\nNCT02755129|Medtronic BRC|Completed|Sep 2016|Jul 2017|Interventional|Mar 2016|Frailty|\\r\\nNCT02754674|Samsung Medical Center|Completed|May 2014|Dec 2017|Interventional|Feb 2015|Rupture|\\r\\nNCT02757521|Washington University School of Medicine|Terminated|Mar 2016|Dec 2016|Interventional|Apr 2016|Disease,Depression,Depressive Disorder,Bipolar Disorder|Nitrous Oxide\\r\\nNCT02750774|University of Modena and Reggio Emilia|Unknown status|Dec 2015|Dec 2016|Interventional|Apr 2016|Diabetes,Obesity,Pregnancy Complications,Fetal Macrosomia,Overweight,Birth Weight|\\r\\nNCT02754739|Samsung Medical Center|Completed|Apr 2014|Aug 2017|Interventional|Apr 2016|Diabetes Mellitus,Prediabetic State|Pravastatin\\r\\nNCT02758808|University of Michigan|Recruiting|Mar 2016|Oct 2023|Observational [Patient Registry]|Apr 2016|Lung Diseases,Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\\r\\nNCT02751840|Tel Hai College|Completed|Oct 2014|Apr 2016|Interventional|Apr 2016|Asymptomatic Diseases|Caffeine\\r\\nNCT02752451|University of Arizona|Completed|Mar 2015|Apr 2015|Interventional|Apr 2016||\\r\\nNCT02757599|Rigshospitalet, Denmark|Completed|Aug 2016|Jun 2017|Interventional|Apr 2016||\\r\\nNCT02753894|Astellas Pharma Inc|Completed|Jan 2008|Jun 2008|Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency,Hyperphosphatemia|\\r\\nNCT02757638|Texas A&M University|Active, not recruiting|Oct 2015|Oct 2021|Interventional|Feb 2016|Weight Loss|\\r\\nNCT02757378|Kevin Farrell|Completed|May 2015|Sep 2015|Interventional|Apr 2016|Back Pain,Low Back Pain|\\r\\nNCT02751489|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|\\r\\nNCT02759315|Merck Sharp & Dohme Corp.|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Uprifosbuvir,Ruzasvir\\r\\nNCT02754895|Massachusetts General Hospital|Completed|Oct 2014|May 2017|Interventional|Apr 2016|Acute Coronary Syndrome,Syndrome|\\r\\nNCT02750475|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\\r\\nNCT02755064|Adil Bharucha|Completed|Jun 2010|Nov 2013|Interventional|Apr 2016|Diabetes Mellitus|Erythromycin,Erythromycin Estolate,Erythromycin Ethylsuccinate,Erythromycin stearate,Erythromycin lactobionate\\r\\nNCT02758002|University of California, San Diego|Withdrawn|Jan 2016|Dec 2018|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02755142|medac GmbH|Completed|Feb 2000|Jun 2001|Interventional|Apr 2016|Glioma,Brain Neoplasms|Aminolevulinic Acid\\r\\nNCT02756364|Millennium Pharmaceuticals, Inc.|Completed|Jul 2016|Nov 2019|Interventional|Apr 2016|Breast Neoplasms|Fulvestrant\\r\\nNCT02759484|Rush University Medical Center|Unknown status|Mar 2015|Mar 2019|Interventional|Dec 2015|Hypertension,Diabetes Mellitus,Hyperglycemia|\\r\\nNCT02752061|Harvard School of Public Health (HSPH)|Completed|May 2016|Jul 2020|Interventional|Apr 2016||\\r\\nNCT02756598|Aarhus University Hospital|Completed|Jan 2015|Jun 2018|Interventional|Dec 2015||Sufentanil,Dsuvia,Propofol\\r\\nNCT02755727|Royal Devon and Exeter NHS Foundation Trust|Completed|Mar 2016|Sep 2017|Interventional|Apr 2016|Tennis Elbow|\\r\\nNCT02754882|Samsung Bioepis Co., Ltd.|Completed|Jul 2016|Oct 2018|Interventional|Mar 2016|Lung Neoplasms,Carcinoma|Paclitaxel,Bevacizumab,Carboplatin\\r\\nNCT02754778|Martin-Luther-Universität Halle-Wittenberg|Completed|Apr 2016|Mar 2021|Interventional|Apr 2016|Pre-Eclampsia,HELLP Syndrome,Syndrome|\\r\\nNCT02758171|Boehringer Ingelheim|Completed|May 2016|Aug 2016|Interventional|Apr 2016||Empagliflozin,Linagliptin\\r\\nNCT02755376|Samsung Medical Center|Completed|Jan 2014|Dec 2018|Interventional|Feb 2015||Hyaluronic Acid\\r\\nNCT02759016|Boehringer Ingelheim|Completed|Jun 2016|Jul 2019|Interventional|Apr 2016|Leukemia|BI 836826\\r\\nNCT02758457|University of Bologna|Completed|Jan 2008|Apr 2015|Interventional|Apr 2016||\\r\\nNCT02755519|Chongqing Medical University|Completed|May 2014|Oct 2016|Observational|Apr 2016|Hyperaldosteronism|\\r\\nNCT02758782|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2021|Interventional|Apr 2016|Spondylitis|Celecoxib,Golimumab\\r\\nNCT02756806|Cutera Inc.|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016||\\r\\nNCT02756156|Kahramanmaras Sutcu Imam University|Unknown status|Apr 2016|Aug 2016|Observational|Mar 2016|Humeral Fractures|\\r\\nNCT02759458|Rush University Medical Center|Completed|Nov 2013|Jan 2017|Interventional|Apr 2016|Rotator Cuff Injuries|\\r\\nNCT02750982|Brown, Theodore R., M.D., MPH|Completed|Jul 2016|Aug 2018|Interventional|Apr 2016|Parkinson Disease,Multiple Sclerosis,Alzheimer Disease,Brain Injuries,Spinal Cord Injuries,Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Huntington Disease,Sclerosis,Wounds and Injuries|\\r\\nNCT02751502|NYU Langone Health|Terminated|Jan 2017|Feb 2021|Interventional|Apr 2016|Hemiplegia|\\r\\nNCT02752087|Eli Lilly and Company|Completed|Apr 2016|May 2016|Interventional|Apr 2016||\\r\\nNCT02756858|Anavex Life Sciences Corp.|Completed|Mar 2016|Nov 2020|Interventional|Mar 2016|Alzheimer Disease|\\r\\nNCT02758249|Konkuk University Medical Center|Completed|Jan 2016|Jan 2016|Interventional|Feb 2016||Propofol,Sevoflurane\\r\\nNCT02754570|University of Colorado, Denver|Completed|Jul 2016|Feb 2018|Interventional|Apr 2016|Glaucoma,Ocular Hypertension,Hypertension|Pilocarpine\\r\\nNCT02754102|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\\r\\nNCT02751593|Peking University People's Hospital|Unknown status|Jan 2016|Dec 2017|Interventional|Apr 2016|Thrombocytopenia,Purpura|Dexamethasone\\r\\nNCT02757014|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\\r\\nNCT02753062|Asan Medical Center|Recruiting|Aug 2015|Aug 2023|Interventional|Apr 2016|Lymphoma|Rituximab,Bendamustine Hydrochloride\\r\\nNCT02752425|Hospices Civils de Lyon|Completed|May 2016|May 2018|Interventional|Apr 2016|Speech Disorders|\\r\\nNCT02757300|Marienhospital Osnabrück|Unknown status|May 2016|Jul 2017|Interventional|Apr 2016|Pharyngitis|\\r\\nNCT02754180|Peking Union Medical College Hospital|Unknown status|Mar 2016|Mar 2021|Interventional|Apr 2016|Adenocarcinoma,Pancreatic Neoplasms|Gemcitabine\\r\\nNCT02752321|Northwell Health|Terminated|Aug 2016|Dec 2017|Interventional|Apr 2016||\\r\\nNCT02753595|Eisai Inc.|Terminated|Jul 2016|Aug 2019|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02755246|Charite University, Berlin, Germany|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016|Cognitive Dysfunction|\\r\\nNCT02754115|Tata Memorial Centre|Recruiting|Apr 2016|Jan 2022|Observational|Mar 2016|Peritoneal Diseases|\\r\\nNCT02756897|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2024|Interventional|Apr 2016|Lymphoma,Leukemia|Venetoclax\\r\\nNCT02752334|Magrabi Eye & Ear Hospital|Completed|Sep 2015|Mar 2019|Interventional|Mar 2016||Magnesium Sulfate,Bupivacaine\\r\\nNCT02754791|Shaare Zedek Medical Center|Unknown status|May 2016|May 2017|Interventional|Apr 2016||\\r\\nNCT02754128|Holland Bloorview Kids Rehabilitation Hospital|Completed|Jun 2016|Oct 2017|Interventional|Apr 2016|Cerebral Palsy|\\r\\nNCT02751190|Umeå University|Completed|Sep 2013|Feb 2017|Observational [Patient Registry]|Apr 2016|Chronic Pain,Hernia|\\r\\nNCT02751645|Oregon Health and Science University|Unknown status|Jun 2016|May 2020|Interventional|Apr 2016||\\r\\nNCT02758184|Duke University|Terminated|Jun 2016|May 2018|Interventional|Apr 2016||\\r\\nNCT02751892|University of East Anglia|Completed|Oct 2013|Sep 2014|Interventional|Apr 2016|Colorectal Neoplasms|\\r\\nNCT02755324|Leiden University|Completed|Oct 2016|Jan 2019|Interventional|Apr 2016|Schistosomiasis|\\r\\nNCT02758886|Washington State University|Completed|Apr 2014||Interventional|Apr 2016|Stress|\\r\\nNCT02750072|Fraser Orthopaedic Research Society|Active, not recruiting|Sep 2016|Apr 2023|Interventional|Apr 2016|Patellofemoral Pain Syndrome,Fractures,Tibial Fractures|\\r\\nNCT02750332|Cycle Pharmaceuticals Ltd.|Completed|Nov 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02752529|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Mar 2016||Interventional|Mar 2016|Liver Cirrhosis|Tacrolimus\\r\\nNCT02759939|Dartmouth-Hitchcock Medical Center|Completed|Jul 2016|Jul 2017|Interventional|Feb 2016||\\r\\nNCT02757157|European Respiratory Society|Terminated|Oct 2016|Jan 2020|Interventional|Apr 2016|Lung Diseases,Pulmonary Disease|\\r\\nNCT02759627|Istanbul University|Completed|Nov 2014|Mar 2016|Interventional|Apr 2016|Stroke|\\r\\nNCT02752412|Sanofi|Completed|May 2016|Oct 2018|Interventional|Apr 2016|Diabetes Mellitus|Insulin,Metformin,Insulin Glargine,Lixisenatide\\r\\nNCT02756988|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\\r\\nNCT02751203|Lara McKenzie|Completed|Apr 2016|Dec 2017|Interventional|Mar 2016||\\r\\nNCT02753946|Nabriva Therapeutics AG|Completed|Apr 2016|May 2017|Interventional|Apr 2016|Infections,Communicable Diseases,Urinary Tract Infections,Pyelonephritis|Tazobactam,Piperacillin,Fosfomycin\\r\\nNCT02755480|University Health Network, Toronto|Terminated|Feb 2015|Feb 2017|Interventional|Mar 2015||\\r\\nNCT02753257|Valtari Bio|Unknown status|Sep 2016|Dec 2019|Observational|Apr 2016|Stroke|\\r\\nNCT02758691|Virginia Polytechnic Institute and State University|Completed|Dec 2015|May 2017|Interventional|Apr 2016||Insulin\\r\\nNCT02755623|Centre hospitalier de Ville-Evrard, France|Unknown status|May 2015|Dec 2018|Interventional|Apr 2016|Hallucinations,Schizophrenia|\\r\\nNCT02756234|Lancaster General Hospital|Completed|May 2016|Aug 2018|Observational|Apr 2016|Coronary Artery Disease|\\r\\nNCT02756091|University Hospital Inselspital, Berne|Recruiting|Aug 2016|May 2022|Observational [Patient Registry]|Apr 2016|Cerebrovascular Disorders|\\r\\nNCT02753491|Marmara University|Completed|Oct 2015|Mar 2016|Interventional|Apr 2016||\\r\\nNCT02752737|Medtronic Cardiac Rhythm and Heart Failure|Recruiting|May 2016|Dec 2024|Observational [Patient Registry]|Apr 2016|Atrial Fibrillation|\\r\\nNCT02758925|University Hospital, Caen|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Lymphoma|Cytarabine,Rituximab,Bendamustine Hydrochloride\\r\\nNCT02751723|Florian Lordick, MD|Unknown status|Sep 2014|Oct 2019|Observational|Apr 2016||\\r\\nNCT02751931|Astellas Pharma Europe B.V.|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Urinary Bladder|Mirabegron\\r\\nNCT02758847|Rabih A. Chaer|Recruiting|Sep 2016|Dec 2022|Interventional|Apr 2016|Ischemia|Paclitaxel,Albumin-Bound Paclitaxel\\r\\nNCT02757807|Eco Fusion|Unknown status|Jul 2016|Dec 2016|Interventional|Apr 2016|Erectile Dysfunction|\\r\\nNCT02755220|Shanghai Cingularbio Co. Ltd|Completed|Jan 2016|Apr 2019|Interventional|Apr 2016||\\r\\nNCT02758548|Novartis Pharmaceuticals|Completed|Mar 2016|May 2016|Interventional|Mar 2016||\\r\\nNCT02756845|Amgen|Recruiting|Aug 2017|Jun 2024|Interventional|Dec 2015|Neoplasms|Talimogene laherparepvec\\r\\nNCT02750605|Skane University Hospital|Active, not recruiting|Feb 2016|Dec 2021|Interventional|Jan 2016|Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Ischemia|\\r\\nNCT02756702|Aesculap AG|Active, not recruiting|Mar 2016|Dec 2022|Observational|Apr 2016|Osteoarthritis|\\r\\nNCT02752945|King's College London|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Depression,Depressive Disorder,Anxiety Disorders|\\r\\nNCT02759952|STZ eyetrial|Enrolling by invitation|Jan 2013|Dec 2025|Observational|Apr 2016|Retinitis,Retinitis Pigmentosa|\\r\\nNCT02754661|Medtronic - MITG|Completed|Sep 2016|Aug 2018|Interventional|Apr 2016|Colorectal Neoplasms|\\r\\nNCT02755441|Nils Hoyer|Recruiting|Apr 2016|Dec 2024|Observational|Apr 2016|Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\\r\\nNCT02750098|Sheba Medical Center|Unknown status|May 2016|Mar 2018|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02753179|Hospices Civils de Lyon|Completed|May 2016|Jan 2017|Interventional|Apr 2016|Vestibular Diseases|\\r\\nNCT02758509|Parc de Salut Mar|Completed|Jan 2010|Oct 2017|Observational|Apr 2016|Hepatitis C,Hepatitis|Interferons,Ritonavir,Ribavirin,Interferon-alpha,Interferon alpha-2,Sofosbuvir,Peginterferon alfa-2a,Ledipasvir,Simeprevir\\r\\nNCT02751970|Universidad de Valparaiso|Unknown status|Apr 2014|Apr 2018|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02753712|Mundipharma Research Limited|Completed|Jun 2016|Aug 2017|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Formoterol Fumarate\\r\\nNCT02751151|Inova Health Care Services|Completed|Feb 2016|May 2021|Interventional|Mar 2016|Skin Neoplasms|Aminolevulinic Acid\\r\\nNCT02757716|Sana Klinikum Offenbach|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Behavior|\\r\\nNCT02758652|Tampere University Hospital|Active, not recruiting|May 2016|May 2026|Observational|Apr 2016|Ovarian Neoplasms,Carcinoma|\\r\\nNCT02754206|Southern Methodist University|Terminated|Jan 2016|Sep 2021|Observational|Apr 2016|Post-Concussion Syndrome,Brain Concussion|\\r\\nNCT02752243|Peter Bader|Active, not recruiting|Mar 2016|Mar 2022|Interventional|Mar 2016|Leukemia,Preleukemia,Myelodysplastic Syndromes,Syndrome,Acute Disease|\\r\\nNCT02754856|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2021|Interventional|Apr 2016|Colorectal Neoplasms|Durvalumab,Ipilimumab,Tremelimumab,Immunoglobulins,Antibodies,Immunoglobulin G\\r\\nNCT02759861|University of Nebraska|Active, not recruiting|Aug 2016|Aug 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Sofosbuvir,Ledipasvir\\r\\nNCT02759679|Haukeland University Hospital|Unknown status|May 2016|Dec 2019|Interventional|Mar 2016|Lung Neoplasms|\\r\\nNCT02752932|Lawson Health Research Institute|Completed|Nov 2015|Oct 2017|Interventional|Feb 2016|Carcinoma,Squamous Cell Carcinoma of Head and Neck,Neoplasms|\\r\\nNCT02759445|RWTH Aachen University|Unknown status|Apr 2016|Oct 2016|Observational|Nov 2015||\\r\\nNCT02754622|Guy's and St Thomas' NHS Foundation Trust|Completed|Jul 2016|Dec 2016|Observational|Apr 2016|Critical Illness|\\r\\nNCT02756611|AbbVie|Active, not recruiting|Jun 2016|Sep 2022|Interventional|Apr 2016|Leukemia|Venetoclax\\r\\nNCT02758223|Wuerzburg University Hospital|Active, not recruiting|Apr 2016|Jun 2021|Interventional|Feb 2016|Leukemia,Myelodysplastic Syndromes|\\r\\nNCT02757079|Nobelpharma|Completed|Jun 2016|Jul 2018|Interventional|Apr 2016|Sleep Wake Disorders,Parasomnias,Disease,Neurodevelopmental Disorders|Melatonin\\r\\nNCT02754219|Dong-A ST Co., Ltd.|Completed|Sep 2016|Jan 2018|Interventional|Apr 2016|Liver Diseases|\\r\\nNCT02753101|Stanford University|Completed|Feb 2016|Feb 2017|Interventional|Apr 2016|Complex Regional Pain Syndromes,Reflex Sympathetic Dystrophy,Sciatica|\\r\\nNCT02759003|Fondazione Salvatore Maugeri|Completed|Mar 2011|Mar 2014|Interventional|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\\r\\nNCT02752659|University of British Columbia|Completed|Jun 2016|Jun 2017|Interventional|Apr 2016|Breast Neoplasms,Lymphedema|\\r\\nNCT02758912|Burnasyan Federal Medical Biophysical Center|Completed|Nov 2016|Oct 2019|Interventional|Apr 2016|Stroke,Angina Pectoris,Infarction,Hemorrhage|\\r\\nNCT02754388|National Taiwan University Hospital|Completed|Feb 2016|Dec 2019|Observational [Patient Registry]|Apr 2016|Lung Neoplasms|\\r\\nNCT02759666|Atridia Pty Ltd.|Completed|Jun 2016|Apr 2019|Interventional|Apr 2016|Neoplasms|\\r\\nNCT02750241|The University of Texas Medical Branch, Galveston|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02752568|Kasr El Aini Hospital|Unknown status|May 2016|Dec 2016|Interventional|Apr 2016||\\r\\nNCT02758015|University of California, San Francisco|Completed|Jun 2016|Mar 2018|Interventional|Apr 2016||Betaine\\r\\nNCT02756884|Arkansas Heart Hospital|Completed|Jun 2015|Jan 2019|Interventional|Apr 2016|Peripheral Arterial Disease,Peripheral Vascular Diseases|\\r\\nNCT02758353|JSI Research & Training Institute, Inc.|Completed|Apr 2015|Nov 2015|Interventional|Apr 2016|Malaria,Stillbirth|\\r\\nNCT02753751|Yale University|Completed|Mar 2018|Jan 2020|Interventional|Apr 2016|Acute Kidney Injury,Wounds and Injuries|\\r\\nNCT02757170|All India In\n\n*** WARNING: max output size exceeded, skipping output. ***\n\nional|Apr 2016||\\r\\nNCT02751047|Seoul National University Hospital|Completed|May 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02758197|Ottawa Hospital Research Institute|Completed|Jul 2016|Oct 2020|Interventional|Apr 2016|Neuralgia,Chronic Pain|\\r\\nNCT02753270|University of Sao Paulo|Completed|Dec 2014|Apr 2017|Interventional|Apr 2016|Varicose Veins|\\r\\nNCT02750839|Azienda Ospedaliera Bolognini di Seriate Bergamo|Unknown status|Apr 2016|Apr 2016|Observational|Apr 2016|Osteoporosis,Fractures,Humeral Fractures|\\r\\nNCT02750488|Bayer|Completed|May 2016|Jul 2016|Interventional|Apr 2016|Dermatitis|\\r\\nNCT02752958|GlaxoSmithKline|Completed|May 2016|Feb 2017|Interventional|Apr 2016|Dentin Sensitivity,Hypersensitivity|Fluorides,Tin Fluorides\\r\\nNCT02753322|The Queen Elizabeth Hospital|Unknown status|Apr 2016|Mar 2018|Interventional|Apr 2016|Stroke|\\r\\nNCT02757261|University of Nove de Julho|Unknown status|Jun 2016|Mar 2017|Interventional|Apr 2016|Bruxism,Sleep Bruxism|Salicylic Acid\\r\\nNCT02754427|University of British Columbia|Completed|Feb 2013|Aug 2015|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02758366|Meyer Children's Hospital|Terminated|Feb 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Astrocytoma,Diffuse Intrinsic Pontine Glioma,Neoplasms|Doxorubicin\\r\\nNCT02755402|Centre hospitalier de l'Université de Montréal (CHUM)|Completed|Jan 2017|May 2021|Interventional|Apr 2016|Hepatitis C|\\r\\nNCT02754453|The Cleveland Clinic|Withdrawn|Jul 2013|Oct 2015|Interventional|Sep 2013|Body Weight,Weight Loss|\\r\\nNCT02755103|Medical University of South Carolina|Active, not recruiting|Jun 2016|Oct 2021|Interventional|Apr 2016|Disease,Substance-Related Disorders,Stress Disorders|\\r\\nNCT02758834|Università Politecnica delle Marche|Completed|Jan 2014|Apr 2016|Observational|Apr 2016|Liver Diseases|\\r\\nNCT02759146|Michigan State University|Completed|May 2016|Nov 2019|Interventional|Apr 2016||\\r\\nNCT02754414|Bloodworks|Unknown status|Apr 2016|Jan 2019|Interventional|Apr 2016||\\r\\nNCT02759783|Royal Marsden NHS Foundation Trust|Active, not recruiting|Nov 2016|Oct 2024|Interventional|Apr 2016|Carcinoma|\\r\\nNCT02756923|Weill Medical College of Cornell University|Suspended|Apr 2012|Dec 2025|Observational|Apr 2016|Infertility|\\r\\nNCT02759237|Medtronic Cardiovascular|Terminated|Feb 2016|May 2017|Observational|Apr 2016|Aortic Valve Stenosis|\\r\\nNCT02757391|M.D. Anderson Cancer Center|Terminated|Aug 2019|Oct 2020|Interventional|Apr 2016|Carcinoma,Colorectal Neoplasms,Adenocarcinoma,Stomach Neoplasms,Esophageal Neoplasms,Cholangiocarcinoma|Aldesleukin,Cyclophosphamide,Pembrolizumab,Interleukin-2,Immunologic Factors\\r\\nNCT02750904|Fred Hutchinson Cancer Research Center|Completed|Apr 2017|May 2019|Interventional|Mar 2016|Disease,Bipolar Disorder|Nicotine\\r\\nNCT02758418|Universitat Jaume I|Unknown status|Apr 2016|Jul 2019|Interventional|Apr 2016|Adjustment Disorders|\\r\\nNCT02756039|AstraZeneca|Completed|May 2016|Aug 2018|Observational|Apr 2016||\\r\\nNCT02755077|Massachusetts General Hospital|Completed|Jul 2014|Jan 2016|Interventional|Apr 2016||\\r\\nNCT02751801|Sheffield Teaching Hospitals NHS Foundation Trust|Completed|Nov 2016|Dec 2017|Observational|Apr 2016|Hypophosphatasia|\\r\\nNCT02751177|Institut de Cancérologie de Lorraine|Completed|Mar 2016|May 2017|Interventional|Mar 2016|Colorectal Neoplasms|\\r\\nNCT02758574|University of Pittsburgh|Completed|May 2016|Aug 2021|Interventional|Mar 2016|Pulmonary Embolism,Embolism|\\r\\nNCT02758587|NHS Greater Glasgow and Clyde|Recruiting|Jul 2017|Dec 2021|Interventional|Apr 2016|Mesothelioma,Carcinoma,Pancreatic Neoplasms|Pembrolizumab\\r\\nNCT02752100|Third Military Medical University|Unknown status|Mar 2016|May 2020|Interventional|Mar 2016|Arterial Occlusive Diseases|\\r\\nNCT02755818|University of California, Davis|Terminated|Oct 2008|Feb 2019|Observational|Mar 2016|Insulin Resistance|Heparin,Calcium heparin\\r\\nNCT02752906|Sanofi Pasteur, a Sanofi Company|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Meningococcal Infections,Meningitis|Vaccines\\r\\nNCT02750371|University Hospital, Bordeaux|Active, not recruiting|Jul 2016|Oct 2021|Interventional|Apr 2016|Adenoma,Meningioma,Pituitary Neoplasms,Pituitary Diseases|\\r\\nNCT02751125|University of Bergen|Completed|Jun 2014|Mar 2020|Interventional|Mar 2016|Atrophy|\\r\\nNCT02754700|High Point University|Completed|Apr 2016|Feb 2019|Interventional|Apr 2016|Knee Injuries|\\r\\nNCT02756442|Assistance Publique Hopitaux De Marseille|Unknown status|Apr 2016|Apr 2019|Interventional|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Diabetes|\\r\\nNCT02756637|Abramson Cancer Center of the University of Pennsylvania|Completed|Apr 2016|Nov 2016|Observational|Apr 2016|Urinary Bladder Neoplasms|\\r\\nNCT02755688|Royal Brompton & Harefield NHS Foundation Trust|Unknown status|Jun 2015|Mar 2020|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02753387|Rennes University Hospital|Completed|May 2016|Sep 2018|Interventional|Apr 2016|Bacterial Infections,Head and Neck Neoplasms|Chlorhexidine\\r\\nNCT02758470|University of British Columbia|Completed|Nov 2016|Jun 2017|Interventional|Apr 2016|Fatigue,Hypoxia|Acetazolamide,Methazolamide\\r\\nNCT02754375|Centre Hospitalier Universitaire de Nice|Unknown status|May 2016|May 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\\r\\nNCT02758756|University of Rochester|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Fatigue|\\r\\nNCT02750787|Abbott Nutrition|Completed|Aug 2016|Jul 2017|Interventional|Apr 2016|Malabsorption Syndromes|\\r\\nNCT02757339|Mclean Hospital|Enrolling by invitation|Jun 2015|May 2022|Observational|Mar 2016|Disease,Stress Disorders,Dissociative Disorders,Dissociative Identity Disorder|\\r\\nNCT02753959|Guy's and St Thomas' NHS Foundation Trust|Completed|Aug 2016|Sep 2019|Interventional|Apr 2016|Neuromuscular Diseases|\\r\\nNCT02753426|University of California, San Francisco|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Kidney Diseases,Renal Insufficiency,Cardio-Renal Syndrome|Doxycycline\\r\\nNCT02757183|AnalyticsPlus, Inc.|Unknown status|Apr 2016|Mar 2017|Observational|Apr 2016||\\r\\nNCT02750293|University of Tromso|Completed|Jun 2015|Sep 2017|Interventional|Apr 2016|Vitamin D Deficiency|Cholecalciferol\\r\\nNCT02757274|European Association of Urology Research Foundation|Recruiting|Feb 2017|Jul 2027|Observational [Patient Registry]|Apr 2016|Urinary Incontinence,Enuresis|\\r\\nNCT02756741|All India Institute of Medical Sciences, New Delhi|Completed|Apr 2014|Jul 2015|Interventional|Apr 2016|Peritonitis,Fibrosis|\\r\\nNCT02758964|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2019|Observational|Apr 2016|Intracranial Embolism,Embolism,Aortic Valve Stenosis|\\r\\nNCT02753439|The Baruch Padeh Medical Center, Poriya|Unknown status|Feb 2017|Feb 2019|Interventional|Mar 2016|Tooth|\\r\\nNCT02751281|Isfahan University of Medical Sciences|Completed|Dec 2014|Apr 2016|Interventional|Apr 2016|Kidney Calculi,Nephrolithiasis|\\r\\nNCT02756676|Ospedale Generale Di Zona Moriggia-Pelascini|Completed|Apr 2015|Dec 2016|Interventional|Apr 2016|Parkinson Disease|\\r\\nNCT02750215|Massachusetts General Hospital|Completed|May 2016|May 2021|Interventional|Apr 2016|Lung Neoplasms|\\r\\nNCT02755935|Cochlear|Completed|May 2016|Sep 2017|Interventional|Apr 2016|Hearing Loss|\\r\\nNCT02759523|Penn State University|Completed|Jul 2013|Dec 2015|Observational|Apr 2016|Pediatric Obesity|\\r\\nNCT02756533|University Hospital, Grenoble|Recruiting|Aug 2016|Aug 2021|Interventional|Mar 2016|Lung Diseases,Pulmonary Disease,Signs and Symptoms|\\r\\nNCT02752841|Brown University|Terminated|May 2016|May 2019|Interventional|Apr 2016|Kidney Calculi,Calculi|Vitamin D\\r\\nNCT02758392|Janssen Research & Development, LLC|Completed|Apr 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02755870|Clene Nanomedicine|Completed|Apr 2015|Oct 2016|Interventional|Apr 2016||\\r\\nNCT02752464|Boston Medical Center|Completed|Sep 2016|Jun 2018|Interventional|Apr 2016||\\r\\nNCT02756780|Royal Marsden NHS Foundation Trust|Unknown status|Apr 2016|Apr 2018|Interventional|Apr 2016||\\r\\nNCT02753998|Assistance Publique - Hôpitaux de Paris|Active, not recruiting|Dec 2016|Sep 2021|Interventional|Apr 2016|Arteriovenous Fistula,Constriction,Fistula|Paclitaxel\\r\\nNCT02751307|Taipei Medical University WanFang Hospital|Completed|May 2013|Jan 2015|Interventional|Apr 2016|Congenital Abnormalities,Metabolic Syndrome,Schizophrenia|Metformin,Clozapine\\r\\nNCT02757755|Armata Pharmaceuticals, Inc.|Completed|May 2016|Aug 2016|Interventional|Apr 2016||\\r\\nNCT02753972|University of New Mexico|Completed|Aug 2006|Jan 2008|Interventional|Apr 2016||\\r\\nNCT02751853|University of Luebeck|Unknown status|Dec 2016|Aug 2020|Interventional|Apr 2016|Heart Failure|\\r\\nNCT02752971|Hospital Central Dr. Luis Ortega|Completed|Feb 2015||Interventional|Mar 2016|Pain|Diclofenac,Bupivacaine\\r\\nNCT02755012|McGill University|Completed|Jun 2012|Nov 2013|Observational|Apr 2016|Infections,Mastitis,Malnutrition,Infant Nutrition Disorders,Growth Disorders,Stress|\\r\\nNCT02751996|F-star Therapeutics, Inc.|Completed|May 2016|Feb 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis B,Hepatitis|Tenofovir\\r\\nNCT02752893|Dartmouth-Hitchcock Medical Center|Completed|Jan 2017|Apr 2019|Observational|Apr 2016|Breast Neoplasms|\\r\\nNCT02753842|Global Protection Corp.|Completed|May 2016|Jul 2017|Interventional|Apr 2016||\\r\\nNCT02757040|Peking University People's Hospital|Unknown status|Dec 2016|Dec 2018|Interventional|Apr 2016|Leukemia|Arsenic Trioxide\\r\\nNCT02751606|Radboud University|Unknown status|Jun 2015|Nov 2019|Interventional|Nov 2014|Neoplasms,Breast Neoplasms,Rectal Neoplasms|\\r\\nNCT02751372|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016||\\r\\nNCT02753764|National Jewish Health|Completed|Jan 2017|Feb 2019|Interventional|Apr 2016|Asthma|Prednisone,AZD7624\\r\\nNCT02758938|University of Wisconsin, Madison|Completed|Jun 2016|Sep 2018|Interventional|Dec 2015|Lower Urinary Tract Symptoms|\\r\\nNCT02752399|Federal University of São Paulo|Unknown status|Apr 2016|Jun 2017|Observational|Apr 2016|Hypertension,Heart Defects,Eisenmenger Complex|\\r\\nNCT02753296|University of Sheffield|Unknown status|May 2016|Jun 2018|Observational|Apr 2016||\\r\\nNCT02759432|Teesside University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02750137|KK Women's and Children's Hospital|Completed|Aug 2014|May 2015|Observational|Apr 2016|Drug-Related Side Effects and Adverse Reactions|Tetracaine\\r\\nNCT02754466|University of Brasilia|Terminated|May 2017|Sep 2021|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02752191|Paul Finn|Recruiting|Apr 2016|Apr 2021|Interventional|Apr 2016|Heart Diseases,Heart Defects|Ferrosoferric Oxide\\r\\nNCT02753517|University Hospital, Lille|Recruiting|Dec 2015|Nov 2023|Interventional|Apr 2016|Liver Failure,Hepatic Insufficiency|\\r\\nNCT02758054|University of Texas Southwestern Medical Center|Active, not recruiting|Jun 2017|Mar 2023|Interventional|Apr 2016|Carcinoma|\\r\\nNCT02757573|Tampere University Hospital|Active, not recruiting|Apr 2016|Dec 2022|Interventional|Apr 2016|Hypercapnia|\\r\\nNCT02752789|National Institute of Allergy and Infectious Diseases (NIAID)|Completed|Jul 2014|Nov 2019|Observational|Apr 2016||\\r\\nNCT02756416|University of Nottingham|Unknown status|Jul 2016|May 2017|Interventional|Mar 2016|Syndrome|\\r\\nNCT02758106|Chung Shan Medical University|Completed|Feb 2014|Nov 2015|Interventional|Apr 2016|Respiratory Insufficiency|\\r\\nNCT02759159|Xuanwu Hospital, Beijing|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Alzheimer Disease|\\r\\nNCT02753777|University of Pennsylvania|Recruiting|Apr 2016|Dec 2025|Observational [Patient Registry]|Apr 2016|Pemphigoid,Pemphigus|\\r\\nNCT02754245|Baylor Research Institute|Unknown status|Nov 2016|Jul 2017|Observational|Apr 2016|Emergencies|\\r\\nNCT02754687|Health Decisions|Unknown status|Apr 2016|Jan 2020|Interventional|Mar 2016||Nandrolone Decanoate,Nandrolone,Nandrolone phenpropionate\\r\\nNCT02755337|Dr. Soetomo General Hospital|Unknown status|Jan 2016|Dec 2016|Observational|Apr 2016|Lung Neoplasms|\\r\\nNCT02755090|University of New Mexico|Completed|Jul 2016|May 2017|Interventional|Apr 2016||Nitrous Oxide\\r\\nNCT02751437|Liverpool Women's NHS Foundation Trust|Completed|Aug 2016|Mar 2018|Interventional|Mar 2016|Premature Birth|\\r\\nNCT02757950|GlaxoSmithKline|Completed|Jul 2016|May 2017|Observational|Apr 2016|Diphtheria|\\r\\nNCT02756754|University Hospital, Toulouse|Completed|Nov 2016|May 2019|Interventional|Apr 2016|Adenoma,Adrenocortical Adenoma,Hyperaldosteronism|\\r\\nNCT02754726|HonorHealth Research Institute|Active, not recruiting|Apr 2016|Jun 2022|Interventional|Apr 2016|Adenocarcinoma|Gemcitabine,Paclitaxel,Nivolumab,Albumin-Bound Paclitaxel\\r\\nNCT02759549|Emory University|Withdrawn|Sep 2015||Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02755714|Haukeland University Hospital|Completed|Jun 2016|Oct 2020|Interventional|Apr 2016||Bromides,Ipratropium\\r\\nNCT02750358|Memorial Sloan Kettering Cancer Center|Active, not recruiting|May 2016|May 2022|Interventional|Apr 2016|Breast Neoplasms,Triple Negative Breast Neoplasms|\\r\\nNCT02754921|Mohamed Sayed Mohamed Abbas|Completed|Jan 2013||Interventional|Apr 2016||\\r\\nNCT02755259|University of Zurich|Completed|Jan 2017|Apr 2019|Interventional|Mar 2016|Hypertension|Acetazolamide\\r\\nNCT02759081|Dalin Tzu Chi General Hospital|Completed|Jan 2015||Interventional|Apr 2016||\\r\\nNCT02755155|University Hospital, Strasbourg, France|Terminated|Sep 2016|Aug 2019|Interventional|Apr 2016|Hypoalbuminemia,Syndrome,Systemic Inflammatory Response Syndrome|\\r\\nNCT02758119|Ilumens|Completed|Jun 2016|Oct 2016|Interventional|Apr 2016|Heart Arrest,Out-of-Hospital Cardiac Arrest|\\r\\nNCT02755415|China Medical University Hospital|Unknown status|May 2016|Dec 2017|Interventional|Apr 2016|Stroke|\\r\\nNCT02751268|Armed Forces Hampyeong Hospital|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Psychomotor Agitation,Emergence Delirium|Ropivacaine\\r\\nNCT02756572|University of Washington|Completed|Sep 2016|Jul 2020|Interventional|Apr 2016|Leukemia,Neoplasms,Preleukemia,Myelodysplastic Syndromes,Anemia,Syndrome|Cytarabine,Cyclosporine,Mycophenolic Acid,Sirolimus,Fludarabine,Fludarabine phosphate,Melphalan,Mechlorethamine,Mitoxantrone,Nitrogen Mustard Compounds,Cladribine,2-chloro-3-deoxyadenosine,Cyclosporins,Lenograstim\\r\\nNCT02756871|Institute of Child Health|Completed|Jul 2015|Feb 2017|Interventional|Apr 2016||\\r\\nNCT02750618|Ultragenyx Pharmaceutical Inc|Completed|May 2016|Sep 2019|Interventional|Dec 2015|Familial Hypophosphatemic Rickets,Hypophosphatemia|\\r\\nNCT02757196|Peking University People's Hospital|Unknown status|May 2016|Dec 2018|Interventional|Apr 2016|Thrombocytopenia,Purpura|Methylprednisolone,Methylprednisolone Acetate,Methylprednisolone Hemisuccinate,Prednisolone,Prednisolone acetate,Rituximab,Prednisolone hemisuccinate,Prednisolone phosphate\\r\\nNCT02758093|University of Alabama at Birmingham|Completed|Sep 2016|Mar 2020|Interventional|Mar 2016||\\r\\nNCT02750943|GlaxoSmithKline|Completed|Nov 2015|Mar 2016|Interventional|Nov 2015|Gingivitis|Fluorides,Tin Fluorides,Fluorophosphate\\r\\nNCT02754908|The University of Hong Kong|Completed|Jan 2016|Jun 2018|Interventional|Apr 2016|Brain Neoplasms|\\r\\nNCT02750514|Bristol-Myers Squibb|Terminated|May 2016|Jan 2020|Interventional|Apr 2016|Carcinoma|Nivolumab,Ipilimumab,Dasatinib,Linrodostat\\r\\nNCT02755350|LVCT Health|Unknown status|Aug 2015|Apr 2017|Interventional|Nov 2015||Emtricitabine\\r\\nNCT02753374|Beijing Children's Hospital|Not yet recruiting|May 2016|Jul 2030|Observational|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02759419|Bayer|Recruiting|Jun 2016|Dec 2023|Interventional|Apr 2016|Pulmonary Arterial Hypertension,Hypertension|Riociguat\\r\\nNCT02757612|Universidad de Murcia|Completed|Jun 2015|Jul 2016|Interventional|Apr 2016|Burning Mouth Syndrome,Syndrome,Burns|\\r\\nNCT02754297|CHU de Quebec-Universite Laval|Recruiting|Apr 2016|Dec 2026|Interventional|Mar 2016|Neoplasms,Neuroendocrine Tumors,Carcinoid Tumor,Carcinoma|Lutetium Lu 177 dotatate\\r\\nNCT02758665|University of Ulm|Active, not recruiting|Sep 2016|Mar 2022|Interventional|Apr 2016|Leukemia|Venetoclax,Obinutuzumab\\r\\nNCT02755285|Fujifilm Medical Systems USA, Inc.|Completed|Aug 2016|Oct 2016|Interventional|Apr 2016||\\r\\nNCT02757690|Asan Medical Center|Completed|Jan 2015|Feb 2016|Interventional|Apr 2016|Neoplasms,Brain Neoplasms|\\r\\nNCT02753218|LEO Pharma|Terminated|Apr 2016|May 2016|Interventional|Apr 2016|Psoriasis|Midazolam\\r\\nNCT02754986|University of Hyogo|Completed|Mar 2015||Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency|\\r\\nNCT02752048|Taiho Pharmaceutical Co., Ltd.|Completed|May 2016|Oct 2017|Interventional|Apr 2016|Muscular Dystrophies,Muscular Dystrophy|\\r\\nNCT02752256|University of Iowa|Completed|Oct 2015|Oct 2017|Observational|Apr 2016||Plasminogen,Tissue Plasminogen Activator\\r\\nNCT02756936|Genuine Research Center, Egypt|Completed|Feb 2016|Mar 2016|Interventional|Apr 2016||\\r\\nNCT02756000|Clinical Hospital Center Zemun|Unknown status|Jan 2016|Jul 2018|Interventional|Apr 2016|Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Infarction|Dobutamine\\r\\nNCT02754492|Terumo BCT|Completed|Apr 2016|Feb 2017|Interventional|Apr 2016||\\r\\nNCT02757677|Swiss Vision Network|Unknown status|Dec 2015|Dec 2019|Observational|Apr 2016|Glaucoma|\\r\\nNCT02752373|Brain Sentinel|Terminated|May 2016|Feb 2017|Observational|Mar 2016|Epilepsy,Seizures|\\r\\nNCT02752230|Kettering Health Network|Withdrawn|Nov 2016|Jun 2021|Interventional|Mar 2016|Pain|\\r\\nNCT02756728|BioInvent International AB|Terminated|May 2016|Dec 2016|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Melphalan\\r\\nNCT02751658|University Hospital, Montpellier|Completed|Nov 2016|Jul 2019|Interventional|Mar 2016|Otorhinolaryngologic Diseases|\\r\\nNCT02754518|University of Chicago|Completed|Apr 2016|Apr 2019|Interventional|Apr 2016|Heart Failure|Valsartan,Sacubitril and valsartan sodium hydrate drug combination\\r\\nNCT02759380|Sahlgrenska University Hospital, Sweden|Recruiting|Mar 2016|Oct 2022|Interventional|Apr 2016|Prostatic Neoplasms|Phytoestrogens\\r\\nNCT02755649|Regeneron Pharmaceuticals|Completed|Jan 2016|Mar 2017|Interventional|Mar 2016|Dermatitis,Eczema|\\r\\nNCT02751827|Institut Bergonié|Completed|Feb 2016|Nov 2019|Observational|Apr 2016||\\r\\nNCT02755545|Galderma Laboratories, L.P.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Acne Vulgaris|Salicylic Acid,Adapalene,Salicylates\\r\\nNCT02750345|Cycle Pharmaceuticals Ltd.|Completed|Mar 2016|May 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02755532|Federal University of São Paulo|Completed|Jan 2014|Oct 2015|Interventional|Apr 2016||Bupivacaine\\r\\nNCT02758743|Biohit Oyj|Completed|Apr 2016|May 2017|Interventional|Apr 2016||\\r\\nNCT02754947|Nationwide Children's Hospital|Completed|Feb 2015|Mar 2016|Observational|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Nervous System Diseases,Cardiovascular Diseases|\\r\\nNCT02750280|Calvary Hospital, Bronx, NY|Completed|Jun 2015|Dec 2015|Interventional|Apr 2016|Diabetic Foot,Foot Ulcer,Ulcer|\\r\\nNCT02756325|NYU Langone Health|Withdrawn|Jun 2016|Jan 2019|Interventional|Apr 2016|Infertility|\\r\\nNCT02758717|Academic and Community Cancer Research United|Active, not recruiting|May 2016|May 2024|Interventional|Apr 2016|Lymphoma,Hodgkin Disease|Antineoplastic Agents,Nivolumab,Brentuximab Vedotin,Antibodies,Immunoglobulins,Immunoconjugates\\r\\nNCT02751034|Medy-Tox|Completed|Jun 2013|Jan 2014|Interventional|Apr 2015||Lidocaine\\r\\nNCT02751476|Action Contre la Faim|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Malnutrition,Severe Acute Malnutrition,Protein-Energy Malnutrition|Disinfectants\\r\\nNCT02755454|University Health Network, Toronto|Completed|Oct 2013|Nov 2018|Interventional|Mar 2016|Lung Neoplasms|\\r\\nNCT02752867|Dongfang Hospital Beijing University of Chinese Medicine|Unknown status|Dec 2016|Nov 2019|Interventional|Mar 2016|Cerebral Infarction,Infarction,Cognitive Dysfunction|\\r\\nNCT02754830|Eli Lilly and Company|Completed|Apr 2016|Jul 2018|Interventional|Apr 2016|Alzheimer Disease|\\r\\nNCT02753738|Medical University of Vienna|Unknown status|Aug 2016||Interventional|Apr 2016||Citalopram\\r\\nNCT02750267|University of Virginia|Completed|May 2016|May 2016|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02754999|Prolong Pharmaceuticals|Completed|Mar 2016|May 2017|Interventional|Apr 2016|Anemia|\\r\\nNCT02754843|Sonova AG|Completed|Oct 2015||Interventional|Oct 2015|Hearing Loss|\\r\\nNCT02759055|HealthPartners Institute|Completed|Oct 2016|Dec 2019|Interventional|Apr 2016|Prediabetic State,Glucose Intolerance|\\r\\nNCT02753673|Memorial Sloan Kettering Cancer Center|Completed|Apr 2016|Apr 2020|Observational|Apr 2016||\\r\\nNCT02754531|Indonesia University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02750033|Seton Healthcare Family|Withdrawn|Oct 2016|Mar 2017|Observational|Apr 2016|Carcinoma|\\r\\nNCT02759133|Centre Antoine Lacassagne|Recruiting|Jun 2016|Nov 2022|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02756650|Novartis Pharmaceuticals|Completed|Jun 2016|Jan 2019|Interventional|Mar 2016|Behcet Syndrome|\\r\\nNCT02752152|Institut de Recherche pour le Developpement|Completed|Dec 2015|Oct 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis B,Syphilis,Hepatitis|\\r\\nNCT02751385|Boehringer Ingelheim|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Carcinoma|Nintedanib,Ethinyl estradiol,Ethinyl Estradiol-Norgestrel Combination\\r\\nNCT02751879|Boehringer Ingelheim|Completed|Nov 2016|Sep 2017|Observational|Apr 2016|Carcinoma|\\r\\nNCT02756663|Novartis Pharmaceuticals|Withdrawn|Dec 2016|Feb 2021|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Dexamethasone,Panobinostat\\r\\nNCT02756273|Centre Hospitalier Universitaire, Amiens|Recruiting|May 2016|May 2022|Interventional|Apr 2016||\\r\\nNCT02755974|Imperial College London|Unknown status|Jan 2009|Apr 2021|Observational|Apr 2016|Lung Diseases,Pulmonary Disease|\\r\\nNCT02756507|Babes-Bolyai University|Completed|Jun 2016|Jun 2018|Interventional|Apr 2016|Disease,Depression,Anxiety Disorders,Panic Disorder|\\r\\nNCT02750553|Jiangsu HengRui Medicine Co., Ltd.|Completed|Jan 2015||Interventional|Apr 2016||\\r\\nNCT02750228|Mednax Center for Research, Education, Quality and Safety|Completed|May 2016|Jun 2020|Observational|Mar 2016|Ductus Arteriosus|\\r\\nNCT02751710|Ontario Clinical Oncology Group (OCOG)|Recruiting|Dec 2016|Dec 2022|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02753361|Suez Canal University|Completed|May 2016|Dec 2016|Interventional|Apr 2016|Lipoma|\\r\\nNCT02753634|Lawson Health Research Institute|Completed|Apr 2015|Jun 2016|Interventional|Mar 2016|Osteoarthritis|\\r\\nNCT02759250|argenx|Completed|Feb 2015|Jun 2018|Interventional|Apr 2016|Nasopharyngeal Carcinoma|\\r\\nNCT02757482|Celal Bayar University|Completed|Sep 2014|Jun 2015|Interventional|Apr 2016||\\r\\nNCT02757105|RedHill Biopharma Limited|Completed|May 2016|Jul 2017|Interventional|Apr 2016|Irritable Bowel Syndrome,Syndrome,Diarrhea|Ondansetron\\r\\nNCT02756520|Fresenius Kabi|Completed|Sep 2016|Oct 2018|Observational|Apr 2016|Kidney Diseases,Renal Insufficiency|\\r\\nNCT02753309|The University of Texas Health Science Center at San Antonio|Completed|Jun 2016|Mar 2021|Interventional|Apr 2016|Urinary Bladder Neoplasms|Sirolimus\\r\\nNCT02756832|Takeda|Completed|Sep 2016|Apr 2018|Observational|Apr 2016|Diabetes Mellitus|Alogliptin\\r\\nNCT02758158|University Health Network, Toronto|Completed|Jan 2016|Feb 2017|Interventional|Mar 2016|Thyroid Neoplasms,Thyroid Nodule,Thyroid Diseases|\\r\\nNCT02752360|Beijing Friendship Hospital|Unknown status|Apr 2016|Dec 2018|Interventional|Apr 2016|Colonic Neoplasms,Crohn Disease,Diverticulum,Diverticular Diseases,Diverticulosis|\\r\\nNCT02757794|Assistance Publique Hopitaux De Marseille|Recruiting|Nov 2016|Jun 2022|Interventional|Apr 2016|Memory Disorders|\\r\\nNCT02751346|Washington University School of Medicine|Completed|Jan 2016|Feb 2017|Observational|Apr 2016|Pain|\\r\\nNCT02757027|Konkuk University Medical Center|Unknown status|May 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02756689|University of Alabama at Birmingham|Completed|Mar 2016|Oct 2017|Interventional|Apr 2016||\\r\\nNCT02751164|Intensive Care National Audit & Research Centre|Completed|Apr 2013|May 2016|Observational|Apr 2016|Critical Illness|\\r\\nNCT02754765|Médecins Sans Frontières, France|Recruiting|Dec 2016|Aug 2023|Interventional|Apr 2016|Tuberculosis,Bacterial Infections|Moxifloxacin,Levofloxacin,Ofloxacin,Linezolid,Pyrazinamide,Bedaquiline,Clofazimine\\r\\nNCT02757729|Amorepacific Corporation|Completed|Oct 2015||Interventional|Apr 2016|Dermatitis,Eczema|\\r\\nNCT02751866|University of Cincinnati|Recruiting|Jan 2016|Jul 2023|Interventional|Apr 2016|Overweight,Hyperphagia|\\r\\nNCT02759068|Hospices Civils de Lyon|Completed|Nov 2014|May 2017|Interventional|Apr 2016|Consciousness Disorders|\\r\\nNCT02752503|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Un\""]}}],"execution_count":0},{"cell_type":"code","source":["RDDclinical= sc.textFile('/FileStore/tables/'+ fileroot2)\nRDDclinical.take(2)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"529cb937-f42d-4565-a6a9-1bc0f7064c24"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[6]: ['Id|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions',\n 'NCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[6]: ['Id|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions',\n 'NCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||']"]}}],"execution_count":0},{"cell_type":"code","source":["RDDmesh= sc.textFile('/FileStore/tables/mesh.csv')\nRDDmesh.take(4)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"22f93966-6257-4d19-9b1c-4e15efd328f6"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[7]: ['term,tree',\n 'Calcimycin,D03.633.100.221.173',\n 'A-23187,D03.633.100.221.173',\n 'Temefos,D02.705.400.625.800']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[7]: ['term,tree',\n 'Calcimycin,D03.633.100.221.173',\n 'A-23187,D03.633.100.221.173',\n 'Temefos,D02.705.400.625.800']"]}}],"execution_count":0},{"cell_type":"code","source":["RDDpharma=sc.textFile('/FileStore/tables/pharma.csv')\nRDDpharma.take(1)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"6591c143-a591-490e-b604-5adc11780b78"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[8]: ['\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[8]: ['\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"']"]}}],"execution_count":0},{"cell_type":"code","source":["clinicalheader= RDDclinical.first()\nCTRDD= RDDclinical.filter(lambda line: line!=clinicalheader)\nCTRDD.take(4)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"d7c3d4b4-af48-4be0-9615-6948fbd74c4e"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[9]: ['NCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||',\n 'NCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|',\n 'NCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|',\n 'NCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[9]: ['NCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||',\n 'NCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|',\n 'NCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|',\n 'NCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|']"]}}],"execution_count":0},{"cell_type":"code","source":["SplitCTline= CTRDD.map(lambda line: line.split('|'))\nSplitCTline.take(1)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"4110eaab-dfa1-421a-8ab7-22cf9c239fed"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[10]: [['NCT02758028',\n  'The University of Hong Kong',\n  'Recruiting',\n  'Aug 2005',\n  'Nov 2021',\n  'Interventional',\n  'Apr 2016',\n  '',\n  '']]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[10]: [['NCT02758028',\n  'The University of Hong Kong',\n  'Recruiting',\n  'Aug 2005',\n  'Nov 2021',\n  'Interventional',\n  'Apr 2016',\n  '',\n  '']]"]}}],"execution_count":0},{"cell_type":"markdown","source":["Answer 1"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"f98bc42e-e5c3-4ed1-8b35-ce37095fb786"}}},{"cell_type":"code","source":["SplitCTline.count()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"f7f3bcf8-f8b8-49e1-a772-86546db4b12c"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[11]: 387261","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[11]: 387261"]}}],"execution_count":0},{"cell_type":"markdown","source":["Question 2 Data Processing"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"fb7ec0ac-96a3-4112-a6e5-1b590fc99b12"}}},{"cell_type":"code","source":["Reduced_RDD= SplitCTline.map(lambda x: (x[5],int(1)))\\\n.reduceByKey(lambda a,b:a+b)\\\n.sortBy(lambda x: x[1], ascending= False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"cd3d1f80-08a5-495f-8882-6c7861284ec4"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["Reduced_RDD.collect()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"89d8a8cd-a962-4655-8afd-1871ca587044"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[13]: [('Interventional', 301472),\n ('Observational', 77540),\n ('Observational [Patient Registry]', 8180),\n ('Expanded Access', 69)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[13]: [('Interventional', 301472),\n ('Observational', 77540),\n ('Observational [Patient Registry]', 8180),\n ('Expanded Access', 69)]"]}}],"execution_count":0},{"cell_type":"markdown","source":["Answer 2"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"f076f676-e2e1-45b3-83fb-a46a9f0bd274"}}},{"cell_type":"code","source":["def Text(data):\n    return ' '.join(str(d) for d in data)\nclinicallines=Reduced_RDD.map(Text)\n\nfor i in clinicallines.collect():\n    print(i)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"f29102dd-2461-405e-ad6d-58f86e0d145d"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Interventional 301472\nObservational 77540\nObservational [Patient Registry] 8180\nExpanded Access 69\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Interventional 301472\nObservational 77540\nObservational [Patient Registry] 8180\nExpanded Access 69\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["Question 3 Data Processing"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"564ecd67-3478-421b-abf8-c094cda71158"}}},{"cell_type":"code","source":["Cond_RDD= SplitCTline.map(lambda x: (x[7]))\\\n.flatMap(lambda x:x.split(','))\\\n.filter(lambda x: x not in [''])\\\n.map(lambda x: (x,1))\\\n.reduceByKey(lambda a,b:a+b)\\\n.sortBy(lambda x: x[1], ascending= False)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"1d65ccf5-7c8b-4405-bc2f-633e0a58fb7c"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["Cond_RDD.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"2df6fa11-9e51-4b75-a3a4-f02914cdd298"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[16]: [('Carcinoma', 13389),\n ('Diabetes Mellitus', 11080),\n ('Neoplasms', 9371),\n ('Breast Neoplasms', 8640),\n ('Syndrome', 8032)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[16]: [('Carcinoma', 13389),\n ('Diabetes Mellitus', 11080),\n ('Neoplasms', 9371),\n ('Breast Neoplasms', 8640),\n ('Syndrome', 8032)]"]}}],"execution_count":0},{"cell_type":"markdown","source":["Answer 3"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"f31d68ae-e306-4f1e-a482-69eadd6ea3a5"}}},{"cell_type":"code","source":["Cond_RDDlines=Cond_RDD.map(Text)\n\nCond_RDDlines.take(5)\nfor i in Cond_RDDlines.take(5):\n    print(i)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"c4263d3b-76b7-443f-9bd9-81e61a4b9506"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Carcinoma 13389\nDiabetes Mellitus 11080\nNeoplasms 9371\nBreast Neoplasms 8640\nSyndrome 8032\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Carcinoma 13389\nDiabetes Mellitus 11080\nNeoplasms 9371\nBreast Neoplasms 8640\nSyndrome 8032\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["Question 4 Data Processing"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"c1d19aad-a78a-4187-9c63-33c397609b72"}}},{"cell_type":"code","source":["meshheader= RDDmesh.first()\nMRDD= RDDmesh.filter(lambda line: line!=meshheader)\nMRDD.take(4)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"5a69ca8a-c0ef-4c74-8d3a-8d3f628b8f50"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[18]: ['Calcimycin,D03.633.100.221.173',\n 'A-23187,D03.633.100.221.173',\n 'Temefos,D02.705.400.625.800',\n 'Temefos,D02.705.539.345.800']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[18]: ['Calcimycin,D03.633.100.221.173',\n 'A-23187,D03.633.100.221.173',\n 'Temefos,D02.705.400.625.800',\n 'Temefos,D02.705.539.345.800']"]}}],"execution_count":0},{"cell_type":"code","source":["Splitmeshline= MRDD.map(lambda line: line.split(','))\nSplitmeshline.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"dfd82a01-7cbf-47ab-aee9-2acb9b2afa00"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[19]: [['Calcimycin', 'D03.633.100.221.173'],\n ['A-23187', 'D03.633.100.221.173'],\n ['Temefos', 'D02.705.400.625.800'],\n ['Temefos', 'D02.705.539.345.800'],\n ['Temefos', 'D02.886.300.692.800']]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[19]: [['Calcimycin', 'D03.633.100.221.173'],\n ['A-23187', 'D03.633.100.221.173'],\n ['Temefos', 'D02.705.400.625.800'],\n ['Temefos', 'D02.705.539.345.800'],\n ['Temefos', 'D02.886.300.692.800']]"]}}],"execution_count":0},{"cell_type":"code","source":["JoinClinicalMesh= Cond_RDD.join(Splitmeshline)\nJoinClinicalMesh.take(4)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"7f920aad-87e4-44e0-8eb9-a7eca4cfd3d1"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[20]: [('Syndrome', (8032, 'C23.550.288.500')),\n ('Lymphoma', (5395, 'C04.557.386')),\n ('Lymphoma', (5395, 'C15.604.515.569')),\n ('Lymphoma', (5395, 'C20.683.515.761'))]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[20]: [('Syndrome', (8032, 'C23.550.288.500')),\n ('Lymphoma', (5395, 'C04.557.386')),\n ('Lymphoma', (5395, 'C15.604.515.569')),\n ('Lymphoma', (5395, 'C20.683.515.761'))]"]}}],"execution_count":0},{"cell_type":"markdown","source":["Answer 4"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"54610e5b-3595-42a6-8823-175116df285d"}}},{"cell_type":"code","source":["Roots=JoinClinicalMesh.map(lambda x: (x[1]))\\\n.map(lambda x: (x[1],x[0]))\\\n.map(lambda x: (x[0].split('.')[0],x[1]))\\\n.reduceByKey(lambda x,y: x+y )\\\n.sortBy(lambda x: x[1], ascending= False)\nRoots.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"d0af6948-52e7-425e-aaad-345f7558be59"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[21]: [('C04', 143994),\n ('C23', 136079),\n ('C01', 106674),\n ('C14', 94523),\n ('C10', 92310)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[21]: [('C04', 143994),\n ('C23', 136079),\n ('C01', 106674),\n ('C14', 94523),\n ('C10', 92310)]"]}}],"execution_count":0},{"cell_type":"code","source":["Root= Roots.map(Text)\n\nRoot.collect()\nfor i in Root.take(5):\n    print(i)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"8c648abd-3833-42c5-96fa-0c6412c3e1a5"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"C04 143994\nC23 136079\nC01 106674\nC14 94523\nC10 92310\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["C04 143994\nC23 136079\nC01 106674\nC14 94523\nC10 92310\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["Question 5 Data Processing"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"ac927462-c227-4be0-98c0-576c27440cf5"}}},{"cell_type":"code","source":["pharmaheader= RDDpharma.first()\npharmaRDD= RDDpharma.filter(lambda line: line!=pharmaheader)\npharmaRDD.take(1)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"d143e106-e253-4150-b217-040c50d09b8a"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[23]: ['\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"']","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[23]: ['\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"']"]}}],"execution_count":0},{"cell_type":"code","source":["Splitpharmaline= pharmaRDD.map(lambda line: line.replace('\"','').split(',')[1])\\\n.map(lambda x: (x,1))\\\n.reduceByKey(lambda x,y: x+y )\nSplitpharmaline.take(2)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"e6744c87-c602-4549-9da5-c08b866aea7b"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[24]: [('Abbott Laboratories', 26), ('AbbVie', 38)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[24]: [('Abbott Laboratories', 26), ('AbbVie', 38)]"]}}],"execution_count":0},{"cell_type":"code","source":["Sponsor_RDD= SplitCTline.map(lambda x: (x[1]))\\\n.map(lambda x: (x,1))\\\n.reduceByKey(lambda x,y: x+y )"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"e5b27874-8be1-4b7e-9edc-7c21a34f1a22"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["Sponsor_RDD.take(2)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"9df0a8ad-dc2f-4490-8faf-914330c81540"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[26]: [('The University of Hong Kong', 757),\n ('Universidade Federal do Rio de Janeiro', 103)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[26]: [('The University of Hong Kong', 757),\n ('Universidade Federal do Rio de Janeiro', 103)]"]}}],"execution_count":0},{"cell_type":"code","source":["Joinclinicalpharma= Sponsor_RDD.subtractByKey(Splitpharmaline)\\\n.sortBy(lambda x: x[1], ascending= False)\nJoinclinicalpharma.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"da8fcb16-b2b2-4039-b41a-602c065945c4"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[27]: [('National Cancer Institute (NCI)', 3218),\n ('M.D. Anderson Cancer Center', 2414),\n ('Assistance Publique - Hôpitaux de Paris', 2369),\n ('Mayo Clinic', 2300),\n ('Merck Sharp & Dohme Corp.', 2243),\n ('Assiut University', 2154),\n ('Novartis Pharmaceuticals', 2088),\n ('Massachusetts General Hospital', 1971),\n ('Cairo University', 1928),\n ('Hoffmann-La Roche', 1828)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[27]: [('National Cancer Institute (NCI)', 3218),\n ('M.D. Anderson Cancer Center', 2414),\n ('Assistance Publique - Hôpitaux de Paris', 2369),\n ('Mayo Clinic', 2300),\n ('Merck Sharp & Dohme Corp.', 2243),\n ('Assiut University', 2154),\n ('Novartis Pharmaceuticals', 2088),\n ('Massachusetts General Hospital', 1971),\n ('Cairo University', 1928),\n ('Hoffmann-La Roche', 1828)]"]}}],"execution_count":0},{"cell_type":"code","source":["def Text2(data):\n    return ' '+':'.join(str(d) for d in data)\nJoinPC= Joinclinicalpharma.map(Text2)\n\nJoinPC.take(10)\nfor i in JoinPC.take(10):\n    print(i)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"7822ac65-9002-4de3-b7db-b9fc35658746"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":" National Cancer Institute (NCI):3218\n M.D. Anderson Cancer Center:2414\n Assistance Publique - Hôpitaux de Paris:2369\n Mayo Clinic:2300\n Merck Sharp & Dohme Corp.:2243\n Assiut University:2154\n Novartis Pharmaceuticals:2088\n Massachusetts General Hospital:1971\n Cairo University:1928\n Hoffmann-La Roche:1828\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":[" National Cancer Institute (NCI):3218\n M.D. Anderson Cancer Center:2414\n Assistance Publique - Hôpitaux de Paris:2369\n Mayo Clinic:2300\n Merck Sharp & Dohme Corp.:2243\n Assiut University:2154\n Novartis Pharmaceuticals:2088\n Massachusetts General Hospital:1971\n Cairo University:1928\n Hoffmann-La Roche:1828\n"]}}],"execution_count":0},{"cell_type":"markdown","source":["Question 6 Data Processing and Answer"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"8aab5b82-db38-4041-b8f0-8537ae646a1f"}}},{"cell_type":"code","source":["MonthRDD= SplitCTline.map(lambda x: (x[2],x[4]))\\\n.filter(lambda x: '2021' in x[1])\\\n.filter(lambda x: 'Completed' in x[0])\\\n.map(lambda x: (x[1],1))\\\n.reduceByKey(lambda x,y: x+y)\\\n.map(lambda x: (x[0].split(' ')[0],x[1]))\\\n.sortByKey(ascending=False)\nMonthRDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"64742a46-1b1c-492b-912d-69cced8b2a88"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[29]: [('Sep', 528),\n ('Oct', 187),\n ('May', 984),\n ('Mar', 1227),\n ('Jun', 1094),\n ('Jul', 819),\n ('Jan', 1131),\n ('Feb', 934),\n ('Aug', 700),\n ('Apr', 967)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[29]: [('Sep', 528),\n ('Oct', 187),\n ('May', 984),\n ('Mar', 1227),\n ('Jun', 1094),\n ('Jul', 819),\n ('Jan', 1131),\n ('Feb', 934),\n ('Aug', 700),\n ('Apr', 967)]"]}}],"execution_count":0},{"cell_type":"code","source":["import calendar\ny = {i:e for e, i  in enumerate(calendar.month_abbr[1:],1)}\n\n#{'Jan':1, 'Feb':2, 'Mar':3, 'Apr':4, 'May':5, 'Jun':6, 'Jul':7, 'Aug':8, 'Sep':9, 'Oct':10, 'Nov':11, 'Dec':12}\n\nMonthRDD2= MonthRDD.sortBy(lambda x: y.get(x[0]))"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"8e646309-f558-4643-b12a-ed7e6002eb71"}},"outputs":[],"execution_count":0},{"cell_type":"code","source":["MonthRDD3= MonthRDD2.map(Text)\n\nMonthRDD3.collect()\nfor i in MonthRDD3.collect():\n    print(i)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"cfea5064-9253-4915-a185-4b36ca42c022"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Jan 1131\nFeb 934\nMar 1227\nApr 967\nMay 984\nJun 1094\nJul 819\nAug 700\nSep 528\nOct 187\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Jan 1131\nFeb 934\nMar 1227\nApr 967\nMay 984\nJun 1094\nJul 819\nAug 700\nSep 528\nOct 187\n"]}}],"execution_count":0},{"cell_type":"code","source":["import matplotlib.pyplot as p\n#get data\nx=[\"Jan\",\"Feb\",\"Mar\",\"Apr\",\"May\",\"Jun\",\"Jul\",\"Aug\",\"Sep\",\"Oct\"]\ny=[1131,934,1227,967,984,1094,819,700,528,187]\n#plot the data\np.plot(x,y, color='Black')\n#Include titles\np.title(\"Studies Completed by Months\")\n#show labels\np.xlabel(\"Month\")\np.ylabel(\"Count of Completed Studies\")\np.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"3e20923f-8c3f-49dd-a09f-d4eb7a528ce0"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"markdown","source":["Additional Analysis"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"3b9303fc-8a9c-4418-a89a-0b481002a83a"}}},{"cell_type":"markdown","source":["Find out the top 10 sponsors and the number of trials sponsored"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"3c02783d-9b4f-464e-96ec-2f5587b93ab7"}}},{"cell_type":"code","source":["Most_Sponsor= Sponsor_RDD.sortBy(lambda x: x[1], ascending= False)\nMost_Sponsor.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"1e5cd35d-4281-41e9-8f5a-45ea19fa22a9"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[33]: [('GlaxoSmithKline', 3378),\n ('National Cancer Institute (NCI)', 3218),\n ('AstraZeneca', 2691),\n ('Pfizer', 2645),\n ('M.D. Anderson Cancer Center', 2414),\n ('Assistance Publique - Hôpitaux de Paris', 2369),\n ('Mayo Clinic', 2300),\n ('Merck Sharp & Dohme Corp.', 2243),\n ('Assiut University', 2154),\n ('Novartis Pharmaceuticals', 2088)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[33]: [('GlaxoSmithKline', 3378),\n ('National Cancer Institute (NCI)', 3218),\n ('AstraZeneca', 2691),\n ('Pfizer', 2645),\n ('M.D. Anderson Cancer Center', 2414),\n ('Assistance Publique - Hôpitaux de Paris', 2369),\n ('Mayo Clinic', 2300),\n ('Merck Sharp & Dohme Corp.', 2243),\n ('Assiut University', 2154),\n ('Novartis Pharmaceuticals', 2088)]"]}}],"execution_count":0},{"cell_type":"code","source":["Most_Sponsor2= Most_Sponsor.map(Text2)\n\nMost_Sponsor2.take(10)\nfor i in Most_Sponsor2.take(10):\n    print(i)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"faf9bdda-82ce-4b28-88ce-8d7daa9c3c13"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":" GlaxoSmithKline:3378\n National Cancer Institute (NCI):3218\n AstraZeneca:2691\n Pfizer:2645\n M.D. Anderson Cancer Center:2414\n Assistance Publique - Hôpitaux de Paris:2369\n Mayo Clinic:2300\n Merck Sharp & Dohme Corp.:2243\n Assiut University:2154\n Novartis Pharmaceuticals:2088\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":[" GlaxoSmithKline:3378\n National Cancer Institute (NCI):3218\n AstraZeneca:2691\n Pfizer:2645\n M.D. Anderson Cancer Center:2414\n Assistance Publique - Hôpitaux de Paris:2369\n Mayo Clinic:2300\n Merck Sharp & Dohme Corp.:2243\n Assiut University:2154\n Novartis Pharmaceuticals:2088\n"]}}],"execution_count":0},{"cell_type":"code","source":["#get data\nx=[\"GSK\",\"NCI\",\"AstraZ\",\"Pfizer\",\"M.D\",\" AP\",\"Mayo\",\"MerckS\",\"Assiut\",\"Nova\"]\ny=[3378,3218,2691,2645, 2414, 2369, 2300, 2243, 2154, 2088]\n#plot the data\np.bar(x,y, color='Green')\n#Include titles\np.title(\"Top 10 Clinicaltrial Sponsors\")\n#show labels\np.xlabel(\"Sponsor's Name\")\np.ylabel(\"Number of Clinicaltrials Sponsored\")\np.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"646be0ed-dbc4-48f1-a261-6738126d877f"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"markdown","source":["Top 5 most frequently fined Pharmaceuticals"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"5711534a-d53d-41ad-b7b1-22be736cb885"}}},{"cell_type":"code","source":["Fined_RDD= pharmaRDD.map(lambda line: line.split('\"')[3])\\\n.map(lambda x: (x,1))\\\n.reduceByKey(lambda a,b:a+b)\\\n.sortBy(lambda x: x[1], ascending= False)\nFined_RDD.take(5)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"2ef3e6e0-3b9c-4edb-a82c-15b6b4c7d74a"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[36]: [('Merck', 78),\n ('Pfizer', 71),\n ('Johnson & Johnson', 59),\n ('Teva Pharmaceutical Industries', 53),\n ('AbbVie', 49)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[36]: [('Merck', 78),\n ('Pfizer', 71),\n ('Johnson & Johnson', 59),\n ('Teva Pharmaceutical Industries', 53),\n ('AbbVie', 49)]"]}}],"execution_count":0},{"cell_type":"code","source":["Finedpharma= Fined_RDD.map(Text)\n\nFinedpharma.take(5)\nfor i in Finedpharma.take(5):\n    print(i)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"fa651403-01fc-4a01-991b-cabe5c3e7adb"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Merck 78\nPfizer 71\nJohnson & Johnson 59\nTeva Pharmaceutical Industries 53\nAbbVie 49\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Merck 78\nPfizer 71\nJohnson & Johnson 59\nTeva Pharmaceutical Industries 53\nAbbVie 49\n"]}}],"execution_count":0},{"cell_type":"code","source":["#get data\nx=[\"Merck\",\"Pfizer\",\"Johnson & Johnson \", \" Teva\",\"AbbVie\"]\ny=[78, 71, 59, 53, 49]\n#plot the data\np.bar(x,y, color='Red')\n#Include titles\np.title(\"Top 5 Offenders\")\n#show labels\np.xlabel(\"Offender's Name\")\np.ylabel(\"Number of times\")\np.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"c75982af-ca46-4cd6-a44a-24cbd91824b7"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"iVBORw0KGgoAAAANSUhEUgAAAX4AAAEWCAYAAABhffzLAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjQuMiwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8rg+JYAAAACXBIWXMAAAsTAAALEwEAmpwYAAAfd0lEQVR4nO3debxVZdn/8c8XcAQVlROhqJiSPjZodSJLn1JRm9WSTDLC4hVPTz3m0K8kyzEt/ZVTv3oqypLSTMMJM0sihzIncADFAScUBTmaJpii4PX7476PLI77nLPPsPY5uL7v12u/9lr3mq61OVx77XutdS1FBGZmVh0D+joAMzNrLCd+M7OKceI3M6sYJ34zs4px4jczqxgnfjOzinHiN+smSbtJWiBpuaQDJA2XdL2kZZJO7+Vt7SFpUW+u06rLid/6XE6cra9XJL1QGD+kl7ZxrqSX2mxrYAfzj5R0vqSnJT0v6RZJH2sz20nAjyJiSERcBkwGngI2joiv9UbcZmVw4rc+lxPnkIgYAjwKfLzQdn4vbur/FrcVEatqzSRpM+DvwEvAW4BhwJnAbyWNK8y6DXB3m/H50c/uipQ0qK9jsP7Fid/6LUnrSTpL0hP5dZak9fK0PSQtknSMpKckPdJbvw6AI4HlwKSIWBIRL0TEBcApwOlKHgTeBFyRfz1cAEwEvpHH95Y0QNIUSQ/mXw4X5S8VJI2SFJImSno078O3Cvu+Qf6V8oyk+cC723w2W0i6WFKLpIclfbUw7QRJ0yWdJ+k54FBJYyTNlvScpCclndFLn5WthZz4rT/7FrArsAuwMzAG+HZh+htJR+NbkpLuVEk7dLC+L0v6p6Q5kg7sYL59gIsj4pU27RcBWwNvjojtWPPXyXjgfFb/qvgLcBhwAPABYAvgGeDHbda5O7ADMBY4TtJ/5Pbjge3y64N5/wCQNAC4Argz7/tY4AhJHyysd39gOjA0x3U2cHZEbJzXeVEH+2+vc0781p8dApwUEUsjogU4EZjQZp5jI2JFRFwHXAkc1M66fgiMBt4AHAucK2m3duYdBiyu0b64ML0eXwK+FRGLImIFcAIwrk3Xy4n5F8WdpES+c24/CDglIv4ZEY/l+Fu9G2iKiJMi4qWIeAj4OXBwYZ4bI+KyiHglIl4AXga2lzQsIpZHxE117oO9DjnxW3+2BbCwML4wt7V6JiKe72D6qyLitoh4OiJWRsQfSUfBn2xnu08BI2q0jyhMr8c2wKWSnpX0LHAPsAoYXphnSWH438CQPLwF8FhhWvFz2AbYonW9ed3HtFlvcVmAScCbgXsl3VrjRLVViBO/9WdPkJJcq61zW6tNJQ3uYHpHAlA70/4CfDJ3qRQdREqo99e5jceAD0fE0MJr/Yh4vI5lFwNbFca3brPeh9usd6OI+EhhnjVOMEfEgtwd9QbgNGB6m8/OKsSJ3/qzC4BvS2qSNAw4DjivzTwnSlpX0n8CHwN+X2tFksZJGpJPuO4LfBaY0c52zwQ2Ac6R9EZJ60saTzrn8PUuXLXzU+AUSdvkGJok7V/nshcB35S0qaSRpPMFrW4Blkk6Op8EHijprZLeXXtVIOmzkpryeYtnc3PbcxhWEU781p+dDMwG5gLzgNtyW6slpBOmT5C6br4UEfe2s67DgcdJSe/7wBcj4tpaM0bE06STrusD84GngaOACRFxYRfiP5v05XK1pGXATcB76lz2RFL3zsPA1cBvCvGtIn3J7ZKnPwX8gvRl1Z4PAXdLWp7jOjj3/VsFqZ9dcmxWF0l7AOdFxMg+DsVsreMjfjOzinHiNzOrGHf1mJlVjI/4zcwqZq0o3jRs2LAYNWpUX4dhZrZWmTNnzlMR0dS2fa1I/KNGjWL27Nl9HYaZ2VpF0sJa7aV29Ug6UtLdku6SdEG+EWZbSTdLekDShZLWLTMGMzNbU2mJX9KWwFeB5oh4KzCQVETqNODMiNiedPPNpLJiMDOz1yr75O4gYINcjXBDUv2RvUjlYgGmkcrWmplZg5SW+HMhqh+QapYvBv4FzAGejYiVebZFpHriryFpcn5wxOyWlpaywjQzq5wyu3o2JT0MYltSidnBpHohdYmIqRHRHBHNTU2vOSltZmbdVGZXz96k0rEtEfEycAmwGzC08CCKkaTCWWZm1iBlJv5HgV0lbShJpMfDzQeuAVofWD0RuLzEGMzMrI0y+/hvJp3EvY1UUncAMBU4GjhK0gPA5sA5ZcVgZmavVeoNXBFxPOmh0UUPkR6abWZmfWCtuHO3R9Te0/XWQi6oZ2a9wEXazMwqxonfzKxinPjNzCrGid/MrGKc+M3MKsaJ38ysYpz4zcwqxonfzKxinPjNzCrGid/MrGKc+M3MKsaJ38ysYpz4zcwqxonfzKxinPjNzCrGid/MrGKc+M3MKqa0J3BJ2gG4sND0JuA44Ne5fRTwCHBQRDxTVhyV5qePmVkNZT5s/b6I2CUidgHeBfwbuBSYAsyKiNHArDxuZmYN0qiunrHAgxGxENgfmJbbpwEHNCgGMzOjcYn/YOCCPDw8Ihbn4SXA8FoLSJosabak2S0tLY2I0cysEkpP/JLWBfYDft92WkQEULPzNiKmRkRzRDQ3NTWVHKWZWXU04oj/w8BtEfFkHn9S0giA/L60ATGYmVnWiMQ/ntXdPAAzgIl5eCJweQNiMDOzrNTEL2kwsA9wSaH5VGAfSQuAvfO4mZk1SGnX8QNExPPA5m3aniZd5WNmZn3Ad+6amVWME7+ZWcU48ZuZVYwTv5lZxTjxm5lVjBO/mVnFOPGbmVWME7+ZWcU48ZuZVYwTv5lZxTjxm5lVjBO/mVnFOPGbmVWME7+ZWcU48ZuZVYwTv5lZxTjxm5lVTNmPXhwqabqkeyXdI+m9kjaTNFPSgvy+aZkxmJnZmso+4j8b+FNE7AjsDNwDTAFmRcRoYFYeNzOzBikt8UvaBHg/cA5ARLwUEc8C+wPT8mzTgAPKisHMzF6rzCP+bYEW4FeSbpf0C0mDgeERsTjPswQYXmIMZmbWRpmJfxDwTuAnEfEO4HnadOtERABRa2FJkyXNljS7paWlxDDNzKqlzMS/CFgUETfn8emkL4InJY0AyO9Lay0cEVMjojkimpuamkoM08ysWkpL/BGxBHhM0g65aSwwH5gBTMxtE4HLy4rBKk56/bzMetGgktd/GHC+pHWBh4DPk75sLpI0CVgIHFRyDGZmVlBq4o+IO4DmGpPGlrldMzNrn+/cNTOrGCd+M7OKceI3M6sYJ34zs4px4jczq5guJX5JAyRtXFYwZmZWvk4Tv6TfSto419m5C5gv6evlh2ZmZmWo54h/p4h4jlRF8ypS8bUJZQZlZmblqSfxryNpHVLinxERL9NOYTUzM+v/6kn8PwMeAQYD10vaBniuzKDMzKw8nZZsiIgfAj8sNC2UtGd5IZmZWZnqObk7XNI5kq7K4zuxurqmmZmtZerp6jkX+DOwRR6/HziipHjMzKxk9ST+YRFxEfAKQESsBFaVGpWZ9UxfPz/AzyLo1+pJ/M9L2px8JY+kXYF/lRqVmZmVpp56/EeRnpq1naQbgCZgXKlRmZlZaeq5quc2SR8AdgAE3Jev5Tczs7VQp4lf0kDgI8CoPP++koiIM0qOzczMSlBPV88VwIvAPPIJ3npJegRYRjoZvDIimiVtBlxI+iJ5BDgoIp7pynrNzKz76kn8IyPi7T3Yxp4R8VRhfAowKyJOlTQljx/dg/WbmVkX1HNVz1WS9u3Fbe4PTMvD00g1gMzMrEHqSfw3AZdKekHSc5KWSaq3Vk8AV0uaI2lybhseEYvz8BJgeK0FJU2WNFvS7JaWljo3Z2Zmnamnq+cM4L3AvIjoalXO3SPicUlvAGZKurc4MSJCUs11RsRUYCpAc3Ozq4GamfWSeo74HwPu6kbSJyIez+9LgUuBMcCTkkYA5PelXV2vmZl1Xz1H/A8B1+YibStaGzu7nDM/sWtARCzLw/sCJ5FuBpsInJrfL+9m7GZmtb1eSj10/Xi7LvUk/ofza938qtdw0rmB1u38NiL+JOlW4CJJk4CFwEFdC9nMzHqinjt3T+zOiiPiIWDnGu1PA2O7s04zM+u5dhO/pLMi4ghJV1DjUYsRsV+pkZmZWSk6OuL/TX7/QSMCMTOzxmg38UfEnDy4S0ScXZwm6XDgujIDMzOzctRzOWetxywe2stxmJlZg3TUxz8e+AywraQZhUkbAf8sOzAzMytHR338/wAWA8OA0wvty4C5ZQZlZmbl6aiPfyHpOvv3Ni4cMzMrWz19/GZm9jrixG9mVjHtJn5Js/L7aY0Lx8zMytbRyd0Rkt4H7Cfpd6QHrb8qIm4rNTIzMytFR4n/OOBYYCSpJn9RAHuVFZSZmZWno6t6pgPTJR0bEd9pYExmZlaieqpzfkfSfsD7c9O1EfGHcsMyM7OydHpVj6TvAYcD8/PrcEnfLTswMzMrRz0PYvkoqVDbKwCSpgG3A8eUGZiZmZWj3uv4hxaGNykhDjMza5B6jvi/B9wu6RrSJZ3vB6bUuwFJA4HZwOMR8TFJ2wK/AzYH5gATIuKlLkduZmbd0ukRf0RcAOwKXAJcDLw3Ii7swjYOB+4pjJ8GnBkR2wPPAJO6sC4zM+uhurp6ImJxRMzIryX1rlzSSNI5gl/kcZGu/5+eZ5kGHNCliM3MrEfKrtVzFvAN4JU8vjnwbESszOOLgC1LjsHMzApKS/ySPgYsLTzCsavLT5Y0W9LslpaWXo7OzKy6Okz8kgZKureb696NVOfnEdLJ3L2As4GhklpPKo8EHq+1cERMjYjmiGhuamrqZghmZtZWh4k/IlYB90nauqsrjohvRsTIiBgFHAz8NSIOAa4BxuXZJgKXd3XdZmbWffVczrkpcLekW4DnWxsjYr9ubvNo4HeSTibdCHZON9djZmbdUE/iP7anG4mIa4Fr8/BDwJiertPMzLqnniJt10naBhgdEX+RtCEwsPzQzMysDPUUafsi6br7n+WmLYHLSozJzMxKVM/lnF8hXaHzHEBELADeUGZQZmZWnnoS/4piLZ18KWaUF5KZmZWpnsR/naRjgA0k7QP8Hrii3LDMzKws9ST+KUALMA/4L+CPwLfLDMrMzMpTz1U9r+SHr9xM6uK5LyLc1WNmtpbqNPFL+ijwU+BBUj3+bSX9V0RcVXZwZmbW++q5get0YM+IeABA0nbAlYATv5nZWqiePv5lrUk/ewhYVlI8ZmZWsnaP+CV9Mg/OlvRH4CJSH/+ngFsbEJuZmZWgo66ejxeGnwQ+kIdbgA1Ki8jMzErVbuKPiM83MhAzM2uMeq7q2RY4DBhVnL8HZZnNzKwP1XNVz2WkmvlXsPrZuWZmtpaqJ/G/GBE/LD0SMzNriHoS/9mSjgeuBla0NkbEbaVFZWZmpakn8b8NmEB6WHprV0/kcTMzW8vUk/g/BbypWJq5HpLWB64H1svbmR4Rx+eTxb8DNgfmABO6um4zM+u+eu7cvQsY2o11rwD2ioidgV2AD0naFTgNODMitgeeASZ1Y91mZtZN9RzxDwXulXQra/bxd3g5Z67guTyPrpNfrV1En8nt04ATgJ90JWgzM+u+ehL/8d1duaSBpO6c7YEfkyp8PhsRK/Msi0jP8K217GRgMsDWW2/d3RDMzKyNeurxX9fdlUfEKmAXSUOBS4Edu7DsVGAqQHNzs+v/m5n1knru3F3G6mfsrkvqsnk+IjaudyMR8ayka4D3AkMlDcpH/SOBx7setpmZdVenJ3cjYqOI2Dgn+g2AA4H/7Ww5SU35SB9JGwD7APcA1wDj8mwTgcu7F7qZmXVHPVf1vCqSy4AP1jH7COAaSXNJZZxnRsQfgKOBoyQ9QLqk85yuhWxmZj1RT1fPJwujA4Bm4MXOlouIucA7arQ/BIzpQoxmZtaL6rmqp1iXfyXwCLB/KdGYmVnp6rmqx3X5zcxeRzp69OJxHSwXEfGdEuIxM7OSdXTE/3yNtsGkEgubA078ZmZroY4evXh667CkjYDDgc+TCqyd3t5yZmbWv3XYxy9pM+Ao4BBSXZ13RsQzjQjMzMzK0VEf//eBT5LKJrwtIpa3N6+Zma09OrqB62vAFsC3gSckPZdfyyQ915jwzMyst3XUx9+lu3rNzGzt4ORuZlYxTvxmZhXjxG9mVjFO/GZmFePEb2ZWMU78ZmYV48RvZlYxTvxmZhXjxG9mVjGlJX5JW0m6RtJ8SXdLOjy3byZppqQF+X3TsmIwM7PXKvOIfyXwtYjYCdgV+IqknYApwKyIGA3MyuNmZtYgpSX+iFgcEbfl4WXAPcCWpOf1TsuzTQMOKCsGMzN7rYb08UsaBbwDuBkYHhGL86QlwPB2lpksabak2S0tLY0I08ysEkpP/JKGABcDR0TEGuWcIyKAqLVcREyNiOaIaG5qaio7TDOzyig18Utah5T0z4+IS3Lzk5JG5OkjgKVlxmBmZmsq86oeAecA90TEGYVJM4CJeXgicHlZMZiZ2Wt1+MzdHtoNmADMk3RHbjsGOBW4SNIkYCFwUIkxmJlZG6Ul/oj4O6B2Jo8ta7tmZtYx37lrZlYxTvxmZhXjxG9mVjFO/GZmFePEb2ZWMU78ZmYV48RvZlYxTvxmZhXjxG9mVjFO/GZmFePEb2ZWMU78ZmYV48RvZlYxTvxmZhXjxG9mVjFO/GZmFePEb2ZWMWU+c/eXkpZKuqvQtpmkmZIW5PdNy9q+mZnVVuYR/7nAh9q0TQFmRcRoYFYeNzOzBiot8UfE9cA/2zTvD0zLw9OAA8ravpmZ1dboPv7hEbE4Dy8Bhrc3o6TJkmZLmt3S0tKY6MzMKqDPTu5GRADRwfSpEdEcEc1NTU0NjMzM7PWt0Yn/SUkjAPL70gZv38ys8hqd+GcAE/PwRODyBm/fzKzyyryc8wLgRmAHSYskTQJOBfaRtADYO4+bmVkDDSprxRExvp1JY8vappmZdc537pqZVYwTv5lZxTjxm5lVjBO/mVnFOPGbmVWME7+ZWcU48ZuZVYwTv5lZxTjxm5lVjBO/mVnFOPGbmVWME7+ZWcU48ZuZVYwTv5lZxTjxm5lVjBO/mVnFOPGbmVWME7+ZWcX0SeKX9CFJ90l6QNKUvojBzKyqGp74JQ0Efgx8GNgJGC9pp0bHYWZWVX1xxD8GeCAiHoqIl4DfAfv3QRxmZpU0qA+2uSXwWGF8EfCetjNJmgxMzqPLJd3XgNi6axjwVOlbkUrfRDeVv/9V3neo9v5733tim1qNfZH46xIRU4GpfR1HPSTNjojmvo6jr1R5/6u871Dt/V+b970vunoeB7YqjI/MbWZm1gB9kfhvBUZL2lbSusDBwIw+iMPMrJIa3tUTESsl/Q/wZ2Ag8MuIuLvRcfSytaJLqkRV3v8q7ztUe//X2n1XRPR1DGZm1kC+c9fMrGKc+M3MKsaJv0BSSDqvMD5IUoukP/TS+pf3xnrKJGmVpDsk3SXp95I2zO1flXSPpPMl7dfbpTY6+mwk7dFb/wY9JekESffmz+cTHcx3rqRxnazrEUnDej/KnpN0c/47eDT/H7gjv0b1dWy9SdIB+f/9jnm83b+1Wn+jkiZKuqBN27D8ma0n6R/lRN4z/fY6/j7yPPBWSRtExAvAPnTxUlNJgyJiZSnRNcYLEbELgKTzgS8BZwBfBvaOiEV5vh5dibU2fk6StgIOIZUaCeCNfRtReSLiPQCSDgWaI+J/+jai0owH/p7fj+/G8pcCp0vaMCL+ndvGAVdExArgfb0TZu/yEf9r/RH4aB4eD7z6bS5psKRfSrpF0u2S9s/th0qaIemvwCxJQyT9StI8SXMlHVjcQD4iuFHSR+nf/gZsL+mnwJuAqyQdmff3RwCFI8E7JL0g6QP1fk5tN6bk+/loep6kTxcmD5E0PR9tny+lWxrzUfOJkm7Ly7QeuX2gENftkjZqb/35KO/aWutvYyWwMTAkIlYWvgQ7JGlsjmFe/lzWK0w+rEbsJ+T5rpX0kKSv5vbBkq6UdGfeh093tP72PpvukrSdpD9JmiPpb5J2lLSJpIWSBhRifEzSOpK+KOnWHO/Fyr8e+wtJQ4DdgUmky8pbbZw/5/sk/bR13/IyZ0q6W9IsSU0R8RxwHfDxwvIHk/OGCr8SJH09fx5zJZ1Y5r51KiL8yi9gOfB2YDqwPnAHsAfwhzz9u8Bn8/BQ4H5gMHAoqfTEZnnaacBZhfVuWlj/cOBmYJ++3t/2PoP8Pgi4HPjvPP4IMCwPHwr8qM1yHyd9UaxT7+dU47M/EJhJusx3OPAoMCL/G/yLdLPfAOBGYPdCXIfl4S8Dv8jDVwC75eEheX+6vP42MW4G3AlcA6zXyed4LunIb31SiZI35/ZfA0d0EvsJwD+A9UhlAZ7On+uBwM8L29ikO+vv4t/Dq//WpC/r0Xn4PcBf8/DlwJ55+NOF/di8sJ6TW2PpLy/Sr7dz8vA/gHflv4UXSQc6A/Pfy7g8TwCH5OHjCp/LOODSPLwF8AQwsM3/p31Jl38q/439AXh/X+27j/jbiIi5wCjS0f4f20zeF5gi6Q7gWtJ/uq3ztJkR8c88vDepAmnrOp/Jg+uQ/vN8IyJmlhB+b9gg799sUmI8p7MFJI0Gvg8cFBEvU//n1NbuwAURsSoiniQdSb07T7slIhZFxCukL+RRheUuye9zCu03AGfko+WhkbqVurv+VucAhwF/BX4raUA+iuuoG2QH4OGIuD+PTwPe30nsAFdGxIqIeApYSvqimgfsI+k0Sf8ZEf/qwfq7JB8dvw/4ff53/RnpSxPgQlLCh3S0e2Eefmv+ZTCPlGTf0t3tl2Q8qUgk+X18Hr4lUhHJVaQj991z+yus3rfzCu1XArtJ2hg4CLg4L1u0b37dDtwG7AiM7t3dqZ/7+GubAfyA9O2/eaFdwIERsUbBOEnvIZ0f6MxK0n/AD5KSTn/0ah9/PXJCuAj4YkQsbm2mZ59TLSsKw6tY8293Rdv2iDhV0pXAR4AbJH2wB+tvtTfp6O96Sf8P+AnwZuBzde9F+9ttb59enRYR90t6J2mfTpY0i3S03Z31d9UA4Nl2/jZmAN+VtBnpqPmvuf1c4ICIuFPpXMEePdh+r8qx7gW8TVKQju6DlMTb3tzU3s1O6WdAxAuS/gR8gvTFd1StTQLfi4if9UL4PeYj/tp+CZwYEfPatP+Z1Cfb2r/8jnaWnwl8pXVE0qZ5MIAvADtKOrp3Q+4zvwR+FRF/K7TV+zm19Tfg05IGSmoiHbne0p2gJG0XEfMi4jRSmZAde2H9c4HP5uFvAGOBFRHxWPuLcB8wStL2eXwC3fzSl7QF8O+IOI/0C+udvbn+jkTqy35Y0qdyLJK0c562nPQZn03qFm092t0IWCxpHdIRf38yDvhNRGwTEaMiYivgYeA/gTFKJWUGkH7J/D0vMyAvB/CZQjukXwZHkX6Z3Vhje38GvpAPlJC0paQ39PZO1cuJv4b8k/+HNSZ9h9RdM1fS3Xm8lpOBTfMJuDuBPQvrXkX6SbmXpC/3cugNJWkb0n+EL2j1idRm6v+cWtcziHRkeikpud5JOmr8RkQs6WZ4R+TPfy7wMnBVL6z/c8CEvM7rSL8KB0qqdYQ3iPSl8CLweVIXyTxSd8FPu7lPbwNuyV0txwMn9/L6O3MIMCn/Td/Nms/RuJD0pXhhoe1Y0vmsG4B7S4qpu8aT/h6KLs7ttwI/Au4hfRm0zvc86UvhLtKvhZMKy84k9e9fGLlTvygirgZ+C9yY/52mk74Y+4RLNlify0eOP4+IMX0dS2/IR4q3AhMiYn5fx2PWlo/4rU9J+hLpZ/K3+zqW3pC7Y+4CbnLSt/7KR/xmZhXjI34zs4px4jczqxgnfjOzinHit35L0khJl0taIOlBSWcrPa6zdfoFue7JkbluTGtdnu16YdtdrqQq6ZEuzHuupMe1uq7OsK4sb9YTTvzWL+Wbvy4BLouI0aQ7ZIcAp+TpbwTeHRFvj4gzgQOA6RHxjoh4sNGxFgt5dcEq0g19Zg3lxG/91V7AixHxK3j1xrcjSTeLbQhcDWyZj/KPB44A/lvSNQCSPqtUHfQOST+TNDC3L5d0ilLFyJskDc/t2ypVTJ0n6eRiIKpRVVHSKKXqjb8mXb65FdCSp9WsolnDWcCR+Qa24vaGKFV/bK2q2VrddJRS9dBzJd2vVEV0b0k35F9FYwrbf011VLNWTvzWX72FVNfoVblswKPA9sB+wIMRsUtEnEi6W/XMiNhT0n+QbrXfLdeWWcXqkgGDSdfY7wxcD3wxt58N/CQi3ga01hxC0r6kYlpjgF2Ad0lqLYI2GvjfiHhLRCyMiNaCbx8CnoiInSPircCf2tnHR0m3/U9o0/4i8ImIeCfpru/T8y8g8r6fTipBsSOpdMDuwP8BjsnzfItUOXNMXv77kga3E4NVkBO/vR6NJRULuzWXNxhLKrML8BKpJC6sWbFyN1Y/e+E3hXV1VFVxYUTcVGP7tapotud7wNdZ8/+iSEXP5gJ/AbYk1YCBVIlzXq4iejcwK5cImFfYl46qo5q5Oqf1W/NZXRALAKWyt1sDDwAdFbgSMC0ivllj2suFWiptK1bWupuxZlVFpUcQ1qw0WquKZkSc1M68C3KCPqjQfAjQBLwrIl7OJ33Xz9OKVTtfKYy/UtiXmtVRzVr5iN/6q1nAhpI+B5D76E8Hzo3Vj7jraNlxytUPJW2WC8p15AZWP4WpWEmyy1UVVbuKZkdOIXXVtNoEWJqT/p5AZ7G31d3qqFYRTvzWL+Wj8k8An5K0gPQUrxdZ3Y/d0bLzSbV/rs7dJTNZ/dCQ9hwOfCVXTtyysK7uVFV8TRXNTuK9m9SN1Op8oDlv73N0vbJll6qjWvW4Vo+ZWcX4iN/MrGKc+M3MKsaJ38ysYpz4zcwqxonfzKxinPjNzCrGid/MrGL+P4TGbSt9jVwWAAAAAElFTkSuQmCC\n"}}],"execution_count":0},{"cell_type":"markdown","source":["Find out the types of offenses committed by pharmaceutical companies and frequency of committing the offences"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"c78c5d87-a8bb-4de0-98e9-66b6985ca801"}}},{"cell_type":"code","source":["Offence_RDD= pharmaRDD.map(lambda line: line.split('\"')[15])\\\n.map(lambda x: (x,1))\\\n.reduceByKey(lambda a,b:a+b)\\\n.sortBy(lambda x: x[1], ascending= False)\nOffence_RDD.take(10)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"1346e779-4d76-4706-80db-8e486b67c7df"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"Out[39]: [('government-contracting-related offenses', 281),\n ('environment-related offenses', 202),\n ('safety-related offenses', 128),\n ('healthcare-related offenses', 128),\n ('competition-related offenses', 103),\n ('employment-related offenses', 72),\n ('consumer-protection-related offenses', 29),\n ('financial offenses', 24),\n ('miscellaneous offenses', 1)]","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":["Out[39]: [('government-contracting-related offenses', 281),\n ('environment-related offenses', 202),\n ('safety-related offenses', 128),\n ('healthcare-related offenses', 128),\n ('competition-related offenses', 103),\n ('employment-related offenses', 72),\n ('consumer-protection-related offenses', 29),\n ('financial offenses', 24),\n ('miscellaneous offenses', 1)]"]}}],"execution_count":0},{"cell_type":"code","source":["Offence_Group= Offence_RDD.map(Text2)\n\nOffence_Group.collect()\nfor i in Offence_Group.collect():\n    print(i)"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"88e9dc23-92cc-4452-9875-070389115b1f"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":" government-contracting-related offenses:281\n environment-related offenses:202\n safety-related offenses:128\n healthcare-related offenses:128\n competition-related offenses:103\n employment-related offenses:72\n consumer-protection-related offenses:29\n financial offenses:24\n miscellaneous offenses:1\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"ansi","arguments":{}}},"output_type":"display_data","data":{"text/plain":[" government-contracting-related offenses:281\n environment-related offenses:202\n safety-related offenses:128\n healthcare-related offenses:128\n competition-related offenses:103\n employment-related offenses:72\n consumer-protection-related offenses:29\n financial offenses:24\n miscellaneous offenses:1\n"]}}],"execution_count":0},{"cell_type":"code","source":["import numpy as np\n#get data\nLabels=[\"government-contracting\",\"environment\",\"healthcare\",\"safety\",\"competition\",\"employment\",\"consumer-protection\",\"financial\",\"miscellaneous\"]\ny=np.array([281,202,128,128,103,72,29,24,1])\n#plot the data\np.pie(y, labels=Labels,autopct= '%1.1f%%')\n#Include titles\np.title(\"Offence Group and Frequencies\")\np.show()"],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"21954692-b38c-4449-8a89-5708b54fd54e"}},"outputs":[{"output_type":"display_data","metadata":{"application/vnd.databricks.v1+output":{"datasetInfos":[],"data":"data:image/png;base64,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\n","removedWidgets":[],"addedWidgets":{},"metadata":{},"type":"image","arguments":{}}},"output_type":"display_data","data":{"image/png":"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\n"}}],"execution_count":0},{"cell_type":"code","source":[""],"metadata":{"application/vnd.databricks.v1+cell":{"title":"","showTitle":false,"inputWidgets":{},"nuid":"857d4d53-af03-4c49-b578-7ed5bf53aace"}},"outputs":[],"execution_count":0}],"metadata":{"application/vnd.databricks.v1+notebook":{"notebookName":"Course Work RDD","dashboards":[],"notebookMetadata":{"pythonIndentUnit":4},"language":"python","widgets":{},"notebookOrigID":2333483257127863}},"nbformat":4,"nbformat_minor":0}
